Methods, systems, and kits for the treatment of inflammatory diseases targeting TL1A
Patent Information
- Application Number
- JP2023553156
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-07-27
- Filing Date
- 2021-11-11
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for inflammatory, fibrostenotic, and fibrotic diseases such as Crohn's disease and ulcerative colitis are inadequate, with many patients not responding to anti-inflammatory therapies, leading to invasive surgeries and significant healthcare burdens, and there is a need for personalized medicine approaches and targeted therapies based on patient genotypes.
The use of inhibitors targeting the TL1A protein, specifically through administering antibodies or fragments that bind to TL1A, based on the detection of specific polymorphisms in the TNFSF15 gene associated with increased TL1A expression, to treat inflammatory diseases like Crohn's disease and ulcerative colitis.
This approach allows for personalized treatment strategies with a positive predictive value of at least 51% specificity, reducing the need for invasive surgeries and improving treatment outcomes for patients with inflammatory bowel diseases.
Abstract
Description
[Background technology]
[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 113,657, filed November 13, 2020, U.S. Provisional Patent Application No. 63 / 136,153, filed January 11, 2021, U.S. Provisional Patent Application No. 63 / 147,165, filed February 8, 2021, U.S. Provisional Patent Application No. 63 / 181,074, filed April 28, 2021, and U.S. Provisional Patent Application No. 63 / 226,032, filed July 27, 2021, each of which is incorporated by reference in its entirety.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format, which is incorporated by reference in its entirety. The ASCII copy, created on November 10, 2021, is named 56884-782_601_SL.txt and is 14,800,566 bytes in size.
[0003] Inflammatory, fibrostenosing, and fibrotic diseases affect millions of people, but their heterogeneous etiologies and diverse clinical manifestations create a significant healthcare burden worldwide. One such disease is inflammatory bowel disease (IBD), of which the two most common forms are Crohn's disease (CD) and ulcerative colitis (UC). IBD is a chronic, relapsing inflammatory disorder of the gastrointestinal tract. The incidence of IBD is high, affecting nearly 3 million people in the United States alone.
[0004] Few treatment options are available for patients suffering from inflammatory, fibrostenosing, and fibrotic diseases. For example, existing anti-inflammatory therapies, such as steroids and tumor necrosis factor (TNF) inhibitors, are often used as first-line treatments for IBD. Unfortunately, a significant number of patients do not respond or lose their response to existing anti-inflammatory therapies, particularly TNF inhibitors. Patients continue to be treated with ineffective anti-inflammatory therapies, and their disease worsens. Surgery, such as structroplasty (reconstruction of the intestinal tract) or surgical resection (removal of the intestinal tract), is the only treatment option for patients who do not respond to first-line treatments. Surgical treatments for IBD are invasive and pose postoperative risks, such as anastomotic leakage, infection, and bleeding, in an estimated one-third of patients undergoing surgery.
[0005] The pathogenesis of inflammatory, fibrostenosing, and fibrotic diseases, such as IBD, is thought to involve uncontrolled immune responses, which can be triggered by specific environmental factors in genetically susceptible individuals. The heterogeneity of disease etiology and clinical course, combined with variable treatment responses and associated side effects, suggests that a personalized medicine approach is the best therapeutic strategy for treating these diseases. However, there are very few personalized therapies available to patients. Therefore, there is a need to identify targeted therapies for the treatment of inflammatory, fibrostenosing, and fibrotic diseases and their underlying phenotypes, as well as to develop reliable methodologies for identifying patients likely to respond to any given therapy based on their genotype. The needed methodology identifies undiagnosed subjects at risk for developing disease, which could allow preventative intervention and reduce the growing healthcare burden. Summary of the Invention
[0006] The genotypes described herein are associated with increased levels of TNFSF15 (TL1A) protein expression in a sample obtained from a subject or patient compared to a reference level of TNFSF15 (TL1A) protein expression (e.g., from a normal individual). The genotypes disclosed herein are located at genes or loci directly or indirectly involved in the TL1A-mediated inflammatory pathway, the T cell-dependent inflammatory pathway. Furthermore, some of the genotypes provided herein are significantly associated with inflammatory bowel disease (IBD), such as Crohn's disease (CD). The genotypes are useful in selecting patients or subjects for treatment with inhibitors of TL1A activity or expression. The patient may be diagnosed with IBD, CD, or both. The subject may be suspected of having IBD, CD, or both.
[0007] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of tumor necrosis factor-like cytokine 1A (TL1A). 1A) activity or expression, wherein at least three polymorphisms that predict a subject's positive therapeutic response to treatment with the inhibitor of TL1A activity or expression with a positive predictive value or specificity of at least about 51% are detected in a sample obtained from the subject, and the inhibitor of TL1A activity or expression is an antibody or antigen-binding fragment thereof that competes for binding to human TL1A with a reference antibody, the antibody or antigen-binding fragment comprising a heavy chain variable region comprising: (a) an HCDR1 having the amino acid sequence set forth in SEQ ID NO: 1, (b) an HCDR2 having the amino acid sequence set forth in any one of SEQ ID NOs: 2 to 5, and (c) an HCDR3 having the amino acid sequence set forth in any one of SEQ ID NOs: 6 to 9, and a light chain variable region comprising: (d) an LCDR1 having the amino acid sequence set forth in SEQ ID NO: 10, (e) an LCDR2 having the amino acid sequence set forth in SEQ ID NO: 11, and (f) an LCDR3 having the amino acid sequence set forth in any one of SEQ ID NOs: 12 to 15.In some embodiments, the at least three polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs22974 37, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0008] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms are selected from the group consisting of rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, and rs1293 4476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457 255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726 , rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof, and at least three polymorphisms are detected in a sample obtained from the subject, and in this case, an inhibitor of TL1A activity or expression comprises: (a) an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1; (b) a heavy chain variable region comprising an HCDR2 having an amino acid sequence set forth in any one of SEQ ID NOs: 2 to 5, and (c) an HCDR3 having an amino acid sequence set forth in any one of SEQ ID NOs: 6 to 9, and a light chain variable region comprising: (d) an LCDR1 having an amino acid sequence set forth in SEQ ID NO: 10, (e) an LCDR2 having an amino acid sequence set forth in SEQ ID NO: 11, and (f) an LCDR3 having an amino acid sequence set forth in any one of SEQ ID NOs: 12 to 15, and an antibody or antigen-binding fragment thereof that competes with a reference antibody for binding to human TL1A.In some embodiments, the at least three polymorphisms include three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0009] In one aspect, a method of treating an inflammatory, fibrotic, or fibrostenotic disease or condition in a subject is disclosed herein, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of the activity or expression of tumor necrosis factor-like cytokine 1A (TL1A), wherein at least three polymorphisms that predict a positive treatment response in the subject to treatment with an inhibitor of the activity or expression of TL1A with at least about 51% positive predictive value or specificity are detected in a sample obtained from the subject, and wherein the inhibitor of the activity or expression of TL1A is an antibody or an antigen-binding fragment thereof that binds to TL1A and comprises: (a) a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 1 for HCDR1, (b) a heavy chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2-5 for HCDR2, and (c) a heavy chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6-9 for HCDR3; and (d) a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 10 for LCDR1, (e) a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 11 for LCDR2, and (f) a light chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 12-15 for LCDR3.In some embodiments, the at least three polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs22974 37, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0010] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms are selected from the group consisting of rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, and rs1 2934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs 12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs 420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof, and at least three polymorphisms are detected in a sample obtained from the subject, and in this case, the inhibitor of TL1A activity or expression comprises (a) an amino acid sequence set forth in SEQ ID NO:1. an antibody or antigen-binding fragment thereof that binds to TL1A, comprising a heavy chain variable region comprising (a) an HCDR1 having the sequence shown in SEQ ID NO: 1, (b) an HCDR2 having the amino acid sequence shown in any one of SEQ ID NOs: 2 to 5, and (c) an HCDR3 having the amino acid sequence shown in any one of SEQ ID NOs: 6 to 9; and a light chain variable region comprising (d) an LCDR1 having the amino acid sequence shown in SEQ ID NO: 10, (e) an LCDR2 having the amino acid sequence shown in SEQ ID NO: 11, and (f) an LCDR3 having the amino acid sequence shown in any one of SEQ ID NOs: 12 to 15.In some embodiments, the at least three polymorphisms include three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0011] In some aspects, disclosed herein are methods for treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms that predict the subject's positive therapeutic response to treatment with the inhibitor of TL1A activity or expression with a positive predictive value or specificity of at least about 51%, and wherein the inhibitor of TL1A activity or expression is an antibody or antigen-binding fragment thereof that binds to tumor necrosis factor-like protein 1A (TL1A), comprising a heavy chain variable domain comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 101-135, or 310-302, and a light chain variable domain comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 201-206, or 303. In some embodiments, the at least three polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs22974 37, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or combinations thereof.In some embodiments, the heavy chain variable domain comprises an amino acid sequence at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 101-135 or 310-302. In some embodiments, the light chain variable domain comprises an amino acid sequence at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 201-206 or 303. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms comprise four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms comprise five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0012] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms are selected from the group consisting of rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs674073 ...892231, rs2070558, rs2070561, rs1892231, rs2070558, rs1892231, rs2070558, rs1892231, rs2070558, rs1892231, rs2070558, rs1892231, rs2070558, rs1892231, rs2070558, rs1892231, s17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750 , rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs152 rs8663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof, and at least three polymorphisms are The inhibitor of TL1A activity or expression is detected in a sample obtained from a subject, and wherein the inhibitor is an antibody or antigen-binding fragment thereof that binds to tumor necrosis factor-like protein 1A (TL1A), comprising a heavy chain variable domain comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 101-135, or 310-302, and a light chain variable domain comprising an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 201-206, or 303. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms comprise four polymorphisms selected from Table 1 (4-SNP model).In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0013] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms that predict a positive therapeutic response in the subject to treatment with an inhibitor of TL1A activity or expression with a positive predictive value or specificity of at least about 51% are detected in a sample obtained from the subject, and wherein the inhibitor of TL1A activity or expression comprises: (a) An antibody or antigen-binding fragment thereof that binds to TL1A, comprising: (a) a heavy chain variable framework region comprising the human IGHV1-46*02 framework or a modified human IGHV1-46*02 framework; and (b) a light chain variable framework region comprising the human IGKV3-20 framework or a modified human IGKV3-20 framework, wherein the heavy chain variable framework region and the light chain variable framework region, in total, comprise modifications of less than about 14 amino acids from the human IGHV1-46*02 framework and the human IGKV3-20 framework.In some embodiments, the at least three polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs22974 37, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0014] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms are selected from the group consisting of rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393 ...892231, rs1892231, rs2070558, rs2070561, rs1892231, rs1892231, rs2070558, rs2070561, rs1892231, rs1892231, rs1892231, rs2070558, rs2070561, rs1892231, rs1892231, rs1892231, rs1892231, rs1892231, rs1892231, rs1892231, rs1892231, rs1892231, s12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476 , rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs169049 2, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof, and at least three polymorphisms are detected in a sample obtained from the subject, and in this case, the inhibitor of TL1A activity or expression comprises: (a) human IGHV1-4 and (b) a heavy chain variable framework region comprising the human IGKV3-20 framework or a modified human IGKV3-20 framework, wherein the heavy chain variable framework region and the light chain variable framework region, in total, comprise modifications of less than about 14 amino acids from the human IGHV1-46*02 framework and the human IGKV3-20 framework.In some embodiments, the amino acid modification of the fewer than 14 amino acid modifications includes: (a) the amino acid modification is at position 47 in the heavy chain variable region, and the amino acid at position 47 is R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; and (b) the amino acid modification is at position 45 in the heavy chain variable region, and the amino acid at position 45 is A, N, D, C, Q, E, G, H, I, L, K, M. , F, P, S, T, W, Y, or V; (c) the amino acid modification is at position 55 in the heavy chain variable region, and the amino acid at position 55 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; and (d) the amino acid modification is at position 78 in the heavy chain variable region, and the amino acid at position 78 is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y. (e) the amino acid modification is at position 80 in the heavy chain variable region, and the amino acid at position 80 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; (f) the amino acid modification is at position 82 in the heavy chain variable region, and the amino acid at position 82 is A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; and (g) the amino acid modification is or (h) the amino acid modification is at position 91 in the heavy chain variable region and the amino acid at position 91 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V, or a combination of two or more modifications selected from (a) to (h). In some embodiments, the amino acid modifications of the less than 14 amino acid modifications include the following in the heavy chain variable region, according to Aho or Kabat numbering: A47R, R45K, M55I, V78A, M80I, R82T, V89A, M91L. In some embodiments, the fewer than 14 amino acid modifications include: (a) a modification at amino acid position 54 in the light chain variable region, and / or (b) a modification at amino acid position 55 in the light chain variable region, according to Aho or Kabat numbering.In some embodiments, the amino acid modification of the fewer than 14 amino acid modifications comprises: (a) the amino acid modification is at position 54 of the light chain variable region, where the amino acid at position 54 is A, R, N, D, C, Q, E, G, H, I, K, M, F, P, S, T, W, Y, or V, and / or (b) the amino acid modification is at position 55 of the light chain variable region, where the amino acid at position 55 is A, R, N, D, C, Q, E, G, H, I, K, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid modification of the fewer than 14 amino acid modifications comprises L54P and / or L55W in the light chain variable region according to Aho or Kabat numbering. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0015] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms that predict a positive therapeutic response in the subject to treatment with the inhibitor of TL1A activity or expression with a positive predictive value or specificity of at least about 51% are detected in a sample obtained from the subject, and wherein the inhibitor of TL1A activity or expression is an antibody or antigen-binding fragment thereof that binds to TL1A and comprises: a heavy chain variable region comprising SEQ ID NO: 301 X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2]RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYCAR[HCDR3]WGQGTTVTVSS; and a light chain variable region comprising: EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK, wherein each of X1-X11 is independently selected from A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, the at least three polymorphisms h comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms h comprise four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms h comprise five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms h comprise six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model).In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0016] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms that predict a positive therapeutic response in the subject to treatment with the inhibitor of TL1A activity or expression with a positive predictive value or specificity of at least about 51% are detected in a sample obtained from the subject, and wherein the inhibitor of TL1A activity or expression is an antibody or antigen-binding fragment thereof that binds to TL1A and comprises: a heavy chain variable region comprising SEQ ID NO: 302 X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2]RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYC[HCDR3]WGQGTTVTVSS; and A light chain variable region comprising: EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK, wherein each of X1 to X11 is independently A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V.In some embodiments, the at least three polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs22974 37, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof. In some embodiments, the at least three polymorphisms comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0017] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms are selected from the group consisting of rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs1243 4976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255 , rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, r s951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or at least 0.and a proxy polymorphism in linkage disequilibrium therewith as determined by R2 of 85, or a combination thereof, and at least three polymorphisms are detected in a sample obtained from the subject, and in this case, the inhibitor of TL1A activity or expression is an antibody or antigen-binding fragment thereof that binds to TL1A and comprises: a heavy chain variable region comprising SEQ ID NO: 301 X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2]RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYCAR[HCDR3]WGQGTTVTVSS; and SEQ ID NO: 303 a light chain variable region comprising: EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK, wherein each of X1-X11 is independently selected from A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, the at least three polymorphisms h comprise three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms h comprise four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms h comprise five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms h comprise six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNP models provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0018] In some aspects, disclosed herein are methods of treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, wherein at least three polymorphisms are selected from the group consisting of rs16901748, rs56124762, rs6478109, rs1892231, and rs207055. 8, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905 , rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, r s2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7 935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914 , rs7278257, or rs11221332, or proxy polymorphisms in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof, and at least three polymorphisms are detected in a sample obtained from the subject, and in this case, the inhibitor of TL1A activity or expression is an antibody or antigen-binding fragment thereof that binds to TL1A and comprises: a heavy chain variable region comprising SEQ ID NO: 302 X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2]RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYC[HCDR3]WGQGTTVTVSS;and a light chain variable region comprising SEQ ID NO: 303 EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK, wherein each of X1-X11 is independently selected from A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V. In some embodiments, (A) X1 is Q or E, (B) X2 is R or K, (C) X3 is A or R, (D) X4 is M or I, (E) X5 is V or A, (F) X6 is M or I, (G) X7 is R or T, (H) X8 is V or A, (I) X9 is M or L, (J) X10 is L or P, (K) X11 is L or W, or (L) X1-X11 are any combination of (a)-(k). In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain CDR1 set forth in SEQ ID NO: 1, a heavy chain CDR2 set forth in any one of SEQ ID NOs: 2 to 5, a heavy chain CDR3 set forth in any one of SEQ ID NOs: 6 to 9, a light chain CDR1 set forth in SEQ ID NO: 10, a light chain CDR2 set forth in SEQ ID NO: 11, and a light chain CDR3 set forth in any one of SEQ ID NOs: 12 to 15. In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain framework (FR) 1 set forth in SEQ ID NO: 304, a heavy chain FR2 set forth in SEQ ID NO: 305 or SEQ ID NO: 313, a heavy chain FR3 set forth in any one of SEQ ID NOs: 306, 307, 314, or 315, a heavy chain FR4 set forth in SEQ ID NO: 308, a light chain FR1 set forth in SEQ ID NO: 309, a light chain FR2 set forth in SEQ ID NO: 310, a light chain FR3 set forth in SEQ ID NO: 311, or a light chain FR4 set forth in SEQ ID NO: 312, or a combination thereof. In some embodiments, the antibody or antigen-binding fragment has one of the following amino acids, according to Kabat numbering: (a) 297A, 297Q, 297G, or 297D; (b) 279F, 279K, or 279L; (c) 228P; (d) 235A, 235E, 235G, 235Q, 235R, or 235S; (e) 237A, 237E, 237K, 237N;or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k) 331S, (l) 236F or 236R, (m) 238A, 238E, 238G, 238H, 238I, 238V, 238W, or 238Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 254I, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265 Y, or 265A, (t) 267G, 267H, 267I, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G, or 292I, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 311S, (ee) 316F, (ff) 328V, ( gg) 330R, (hh) 339E or 339L, (ii) 343I or 343V, (jj) 373A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (ll) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 434I, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 44 0D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgG1σ, (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R,In some embodiments, the antibody or antigen-binding fragment comprises a human IgG1 Fc region comprising: (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (lll) A330L, (mmm) P331A or P331S, or (nnn) any combination of two or more selected from (a)-(uu). In some embodiments, the antibody or antigen-binding fragment comprises a human IgG4 Fc region. In some embodiments, the antibody or antigen-binding fragment comprises an Fc region comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 320-362. In some embodiments, the antibody or antigen-binding fragment comprises a fragment crystallizable (Fc) region that has reduced antibody-dependent cell-mediated cytotoxicity (ADCC) function compared to human IgG1 and / or reduced complement-dependent cytotoxicity (CDC) compared to human IgG1. In some embodiments, the Fc comprises a human IgG1 comprising SEQ ID NO: 320. In some embodiments, the ADCC function of the Fc region with reduced ADCC is reduced by at least about 50% compared to human IgG1. In some embodiments, the CDC function of the Fc region with reduced CDC is reduced by at least about 50% compared to human IgG1. In some embodiments, the Fc comprises (i) a human IgG4 Fc region, or (ii) a human IgG4 Fc region comprising, according to Kabat numbering, (a) S228P, (b) S228P and L235E, or (c) S228P, F234A, and L235A. In some embodiments, the Fc comprises a human IgG2 Fc region; an IgG2-IgG4 cross-subclass Fc region; an IgG2-IgG3 cross-subclass Fc region; an IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or an IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2σ). In some embodiments, the Fc comprises the residues 329A, 329G, 329Y, 331S, 236F, 236R, 238A, 238E, 238G, 238H, 238I, 238V, 238W, 238Y ...and a human IgG1 comprising a substitution selected from 238Y, 248A, 254D, 254E, 254G, 254H, 254I, 254N, 254P, 254Q, 254T, 254V, 264S, 265H, 265K, 265S, 265Y, 265A, 267G, 267H, 267I, 267K, 434I, 438G, 439E, 439H, 439Q, 440A, 440D, 440E, 440F, 440M, 440T, and 440V. In some embodiments, the Fc comprises a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 320-362. In some embodiments, the Fc comprises any one of SEQ ID NOs: 401-413, or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 401-413. In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain comprising any one of SEQ ID NOs: 501-513, or a heavy chain comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 501-513. In some embodiments, the antibody or antigen-binding fragment comprises a light chain comprising any one of SEQ ID NOs: 514, or a light chain comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 514. In some embodiments, the at least three polymorphisms predict a positive therapeutic response with a positive predictive value and specificity of at least about 51%. In some embodiments, the positive predictive value is about 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% or greater. In some embodiments, the positive predictive value is about 60% to 100%, 65% to 95%, 70% to 90%, 75% to 85%, and 70% to 80%. In some embodiments, the specificity is about 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,The specificity is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% or greater. In some embodiments, the specificity is about 60% to 100%, 65% to 95%, 70% to 90%, 75% to 85%, and 70% to 80%. In some embodiments, the at least three polymorphisms include rs6478109, rs56124762, and rs1892231. In some embodiments, the at least three polymorphisms include rs6478109, rs56124762, and rs16901748. In some embodiments, the at least three polymorphisms include rs6478109, rs1892231, and rs16901748. In some embodiments, the at least three polymorphisms include rs56124762, rs1892231, and rs16901748. In some embodiments, the at least three polymorphisms include rs6478109, rs2070558, and rs1892231. In some embodiments, the at least three polymorphisms include rs6478109, rs2070558, and rs16901748. In some embodiments, the at least three polymorphisms include rs6478109, rs1892231, and rs16901748. In some embodiments, the at least three polymorphisms include rs2070558, rs1892231, and rs16901748. In some embodiments, the at least three polymorphisms include rs6478109, rs2070561, and rs1892231. In some embodiments, the at least three polymorphisms include rs6478109, rs2070561, and rs16901748. In some embodiments, the at least three polymorphisms include rs6478109, rs1892231, and rs16901748. In some embodiments, the at least three polymorphisms include rs2070561, rs1892231, and rs16901748. In some embodiments, the at least three polymorphisms include rs6478109, rs7935393, and rs1892231. In some embodiments, the at least three polymorphisms include rs6478109, rs7935393, and rs9806914. In some embodiments, the at least three polymorphisms include rs6478109, rs7935393, and rs7278257. In some embodiments, the at least three polymorphisms include rs6478109, rs7935393, and rs2070557. In some embodiments, the at least three polymorphisms include rs6478109, rs1892231, and rs9806914. In some embodiments, the at least three polymorphisms include rs6478109, rs1892231, and rs7278257.In some embodiments, the at least three polymorphisms include rs6478109, rs1892231, and rs2070557. In some embodiments, the at least three polymorphisms include rs6478109, rs9806914, and rs7278257. In some embodiments, the at least three polymorphisms include rs6478109, rs9806914, and rs2070557. In some embodiments, the at least three polymorphisms include rs6478109, rs7278257, and rs2070557. In some embodiments, the at least three polymorphisms include rs7935393, rs1892231, and rs9806914. In some embodiments, the at least three polymorphisms include rs7935393, rs1892231, and rs7278257. In some embodiments, the at least three polymorphisms include rs7935393, rs1892231, and rs2070557. In some embodiments, the at least three polymorphisms include rs7935393, rs9806914, and rs7278257. In some embodiments, the at least three polymorphisms include rs7935393, rs9806914, and rs2070557. In some embodiments, the at least three polymorphisms include rs7935393, rs7278257, and rs2070557. In some embodiments, the at least three polymorphisms include rs1892231, rs9806914, and rs7278257. In some embodiments, the at least three polymorphisms include rs1892231, rs9806914, and rs2070557. In some embodiments, the at least three polymorphisms include rs1892231, rs7278257, and rs2070557. In some embodiments, the at least three polymorphisms include rs9806914, rs7278257, and rs2070557. In some embodiments, the at least three polymorphisms include rs6478109, rs56124762, and rs1892231.In some embodiments, the at least three polymorphisms further comprise: rs16901748, rs1892231, rs56124762, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, and a fourth polymorphism comprising rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or a proxy polymorphism in linkage disequilibrium therewith as determined by an R2 of at least 0.85, or a combination thereof. In some embodiments, the at least three polymorphisms are detected in a sample by subjecting the sample to an assay configured to detect the presence of at least three nucleotides corresponding to nucleic acid position 501 in at least three of SEQ ID NOs: 2001-20041, or 20057-20059. In some embodiments, the inflammatory, fibrotic, or fibrostenosing disease or condition includes inflammatory bowel disease, Crohn's disease, obstructive Crohn's disease, ulcerative colitis, intestinal fibrosis, intestinal fibrostenosis, rheumatoid arthritis, pulmonary fibrosis, scleroderma, or primary sclerosing cholangitis. In some embodiments, the Crohn's disease is ileal, ileocolic, or chronic Crohn's disease. In some embodiments, the pulmonary fibrosis includes idiopathic pulmonary fibrosis.In some embodiments, the subject has or is at risk of developing non-responsiveness or loss of responsiveness to standard therapies, including glucocorticosteroids, anti-TNF therapy, anti-a4-b7 therapy, anti-IL12p40 therapy, or a combination thereof. In some embodiments, the method further includes determining whether the subject, having an inflammatory, fibrotic, or fibrostenosing disease or condition, is suitable for treatment with an inhibitor of TL1A activity or expression, based at least in part on the at least three polymorphisms detected in the sample. In some embodiments, the method further includes obtaining a sample from the subject or having obtained a sample from the subject. In some embodiments, the at least three polymorphisms are detected using an assay including quantitative polymerase chain reaction (qPCR), a nucleic acid sequencing reaction, or a genotyping array. In some embodiments, the at least three polymorphisms include three polymorphisms selected from Table 1 (3-SNP model). In some embodiments, the at least three polymorphisms include four polymorphisms selected from Table 1 (4-SNP model). In some embodiments, the at least three polymorphisms include five polymorphisms selected from Table 1 (5-SNP model). In some embodiments, the at least three polymorphisms include six polymorphisms selected from Table 1 (6-SNP model). In some embodiments, the at least three polymorphisms include seven polymorphisms selected from Table 1 (7-SNP model). In some embodiments, the at least three polymorphisms include eight polymorphisms from one or more 8-SNPs provided in Table 25. In some embodiments, the at least three polymorphisms include nine polymorphisms selected from Table 1 (9-SNP model). In some embodiments, the at least three polymorphisms include ten polymorphisms selected from Table 1 (10-SNP model).
[0019] In further embodiments, the at least three polymorphisms are at least eight polymorphisms. In some embodiments, the at least eight polymorphisms are provided in the 8-SNP model of Table 25.
[0020] Further aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description. In the following detailed description, only illustrative embodiments of the present disclosure are shown and described. As will be understood, the present disclosure is capable of other and different embodiments, and its several details can be modified in various obvious respects, all without departing from the present disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
[0021] Incorporation by Reference All publications, patents, and patent applications mentioned herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that the publications and patents or patent applications incorporated by reference conflict with the disclosure contained herein, the present specification is intended to supersede and / or precede any such conflicting content. [Brief explanation of the drawings]
[0022] The novel concepts of the present invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "figures").
[0023] [Figure 1] FIG. 1 illustrates a workflow according to an embodiment of the present disclosure for processing a biological sample obtained from a subject to inform the selection of a therapeutic agent for treating a disease or condition in the subject. [Figure 2] FIG. 2 shows a computer-implemented workflow according to an embodiment of the present disclosure for generating an electronic report to a user, such as a physician, that includes a subject's TNFSF15 profile based on an analysis of genotype data from the subject. [Figure 3]FIG. 3 illustrates a computer system programmed or otherwise configured to perform the methods provided herein. [Figure 4] FIG. 4 shows a computer-implemented workflow according to an embodiment of the present disclosure for creating a TNFSF15 profile. [Figure 5A] 5A-5C show clustering analysis within our TL1A companion diagnostic (CDx) dataset, according to some embodiments herein. Figure 5A shows cluster 1, Figure 5B shows cluster 2, and Figure 5C shows cluster 3 from the TL1A CDx dataset. [Figure 5B] 5A-5C show clustering analysis within our TL1A companion diagnostic (CDx) dataset, according to some embodiments herein. Figure 5A shows cluster 1, Figure 5B shows cluster 2, and Figure 5C shows cluster 3 from the TL1A CDx dataset. [Figure 5C] 5A-5C show clustering analysis within our TL1A companion diagnostic (CDx) dataset, according to some embodiments herein. Figure 5A shows cluster 1, Figure 5B shows cluster 2, and Figure 5C shows cluster 3 from the TL1A CDx dataset. [Figure 6] FIG. 6 shows that the three clusters in FIGS. 5A-5C were collapsed into two clusters: a high TL1A expression cluster shown on the left and a low TL1A expression cluster shown on the right. [Figure 7A] Figures 7A-7C show chromatograms of analytical size-exclusion chromatography of anti-TL1A antibodies: Figure 7A shows chromatograms of analytical size-exclusion chromatography of antibodies A193, A194, and A195. [Figure 7B] Figures 7A-7C show chromatograms of analytical size-exclusion chromatography of anti-TL1A antibodies, and Figure 7B shows chromatograms of analytical size-exclusion chromatography of antibodies A196, A197, and A198. [Figure 7C]Figures 7A-7C show chromatograms of analytical size-exclusion chromatography of anti-TL1A antibodies, and Figure 7C shows chromatograms of analytical size-exclusion chromatography of antibodies A199, A200, and A201. [Figure 8A] Figures 8A and 8B show the inhibition of interferon gamma in human blood using anti-TL1A antibodies: Figure 8A shows the inhibition of interferon gamma in human blood using anti-TL1A antibodies A219 and A213. [Figure 8B] Figures 8A and 8B show the inhibition of interferon gamma in human blood using anti-TL1A antibodies. Figure 8B shows the inhibition of interferon gamma in human blood using anti-TL1A antibody A212. [Figure 9A] Figures 9A-9C show PLS models demonstrating the effect of pH and protein concentration on viscosity. Figure 9A shows the PLS graph, Figure 9B shows the model of predicted viscosity compared to anti-TL1A antibody concentration in mg / mL, and Figure 9C shows the model of estimated viscosity compared to actual viscosity. Viscosity units are mPa-s. [Figure 9B] Figures 9A-9C show PLS models demonstrating the effect of pH and protein concentration on viscosity. Figure 9A shows the PLS graph, Figure 9B shows the model of predicted viscosity compared to anti-TL1A antibody concentration in mg / mL, and Figure 9C shows the model of estimated viscosity compared to actual viscosity. Viscosity units are mPa-s. [Figure 9C] Figures 9A-9C show PLS models demonstrating the effect of pH and protein concentration on viscosity. Figure 9A shows the PLS graph, Figure 9B shows the model of predicted viscosity compared to anti-TL1A antibody concentration in mg / mL, and Figure 9C shows the model of estimated viscosity compared to actual viscosity. Viscosity units are mPa-s. [Figure 10] FIG. 10 shows TL1A CDx performance statistics for the TL1A in vitro production assay, according to some embodiments. [Figure 11A]11A-11B show exemplary clinical trials for anti-TL1A antibodies disclosed herein. Figure 11A shows the lead-in period study schema for a Phase II clinical trial for A219 in UC, according to some embodiments of the present disclosure. [Figure 11B] 11A-11B show exemplary clinical trials for anti-TL1A antibodies disclosed herein. Figure 11B shows the study schema for an open-label extension period for a Phase II clinical trial for A219 in UC, according to some embodiments of the present disclosure. DETAILED DESCRIPTION OF THE INVENTION
[0024] Provided herein are methods, systems, and kits for treating a subject who may be suitable for treatment with an inhibitor of Tumor Necrosis Factor (Ligand) Superfamily, Member 15 (TL1A) activity or expression, provided that the subject is a carrier of the genotype. The subject may be a patient who may be diagnosed with an inflammatory, fibrostenosing, or fibrotic disease, such as inflammatory bowel disease (IBD) or Crohn's disease (CD). The subject may not be a patient, but may be suspected of having an inflammatory, fibrostenosing, or fibrotic disease. The genotype may, in some instances, be useful for treating inflammatory, fibrostenosing, or fibrotic diseases or conditions mediated by TL1A. In some embodiments, the subject is treated by administering an inhibitor of TL1A activity or expression (e.g., an anti-TL1A antibody), provided that the genotype is detected. In some instances, administering the inhibitor to the subject requires identifying the subject as suitable for treatment with the activity or expression inhibitor.
[0025] With reference to FIG. 1 , the methods, systems, and kits of the present disclosure, in some embodiments, involve the steps of providing a buccal swab sample from a subject at step 101, optionally processing the sample to purify DNA from the sample at step 102, analyzing the optionally processed sample to detect genotypes of at least three genetic agents in the sample at step 103, processing the genotypes to generate a TNFSF15 profile at step 104, and treating the subject with an anti-TL1A antibody or antibody fragment disclosed herein based on the TNFSF15 profile to treat the subject's disease or condition at step 105.
[0026] The genotypes described herein are detected using a suitable genotype determination device (e.g., array, sequencing). In some cases, the sample is obtained indirectly or directly from the subject or patient. In some cases, the sample may be obtained by the subject. In other cases, the sample may be obtained by a medical professional such as a nurse or doctor. The sample may be derived from virtually any biological fluid or tissue that contains genetic information, such as blood.
[0027] The subject disclosed herein may be, for example, a mammal, such as a mouse, a rat, a guinea pig, a rabbit, a non-human primate, or a livestock animal.In some examples, the subject is a human.In some examples, the subject suffers from symptoms associated with the disease or condition disclosed herein (e.g., abdominal pain, cramps, diarrhea, rectal bleeding, fever, weight loss, fatigue, loss of appetite, dehydration, and malnutrition, anemia, or ulcer).
[0028] In some embodiments, the subject is susceptible to or suffers from thiopurine toxicity or a disease caused by thiopurine toxicity (e.g., pancreatitis or leukopenia). The subject may be or is suspected of experiencing non-responsiveness or loss of responsiveness to standard treatment (e.g., anti-TNF-alpha therapy, anti-a4-b7 therapy (vedolizumab), anti-IL12p40 therapy (ustekinumab), thalidomide, or cytoxin).
[0029] The disease or condition disclosed herein may be an inflammatory disease, a fibrostenosing disease, or a fibrotic disease. In some examples, the disease or condition is a TL1A-mediated disease or condition. The term "TL1A-mediated disease or condition" refers to a disease or pathological or pathogenic condition that is at least partially caused by TL1A signaling. In some examples, the disease or condition is an immune-mediated disease or condition, such as one mediated by TL1A.
[0030] In some embodiments, the disease or condition is an inflammatory disease or disorder mediated at least in part by TL1A signaling. Non-limiting examples of inflammatory diseases include allergies, ankylosing spondylitis, asthma, atopic dermatitis, autoimmune diseases or disorders, cancer, celiac disease, chronic obstructive pulmonary disease (COPD), chronic peptic ulcer disease, cystic fibrosis, diabetes (e.g., type 1 diabetes and type 2 diabetes), glomerulonephritis, gout, hepatitis (e.g., active hepatitis), immune-mediated diseases or disorders, such as inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, myositis, osteoarthritis, pelvic inflammatory disease (PID), multiple sclerosis, age-related neurodegenerative diseases, periodontal disease (e.g., periodontitis), preperfusion injury, transplant rejection, psoriasis, pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), rheumatic diseases, scleroderma, sinusitis, and tuberculosis.
[0031] In some embodiments, the disease or condition is an autoimmune disease mediated at least in part by TL1A signaling. Non-limiting examples of autoimmune diseases or disorders include achalasia, Addison's disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy (AMAN). neuropathy), Barrow's disease, Behçet's disease, benign mucous membrane pemphigoid, bullous pemphigoid, Castleman's disease (CD), celiac disease, Chagas' disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS), or eosinophilic granulomatosis (EGPA) Granulomatosis, cicatricial pemphigoid, Cogan's syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schönlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG)gestations), hidradenitis suppurativa (HS) (inverse acne), hypogammaglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, lignified conjunctivitis, linear immunoglobulin A disease (LAD), lupus erythematosus, Lyme disease, chronic Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD). disease), Mooren's ulcer, Mucher-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Romberg's syndrome (Parry Romberg's syndrome) syndrome), pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, polyglandular syndrome types I, II and III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, post-pericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progestational dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS) , retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm and testicular autoimmunity, stiff-person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac syndrome, sympathetic ophthalmia (SO), Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), transverse myelitis, type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, and Vogt-Koyanagi-Harada disease.
[0032] In some embodiments, the disease or condition is a cancer mediated at least in part by TL1A signaling. Non-limiting examples of cancers include adenoid cystic carcinoma, adrenal cancer, amyloidosis, anal cancer, ataxia telangiectasia, atypical nevus syndrome, basal cell carcinoma, biliary sputum, Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain tumor, breast cancer, male breast cancer, carcinoid tumor, cervical cancer, colorectal cancer, ductal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumor (GIST), HER2-positive breast cancer, pancreatic islet cell tumor, juvenile polyposis syndrome, kidney cancer, laryngeal cancer, leukemia-acute lymphoblastic leukemia, leukemia-acute lymphocytic (ALL), leukemia-acute myeloid AML, leukemia-adult, leukemia-pediatric, leukemia-chronic lymphocytic (CLL), leukemia-chronic myeloid (CML), liver cancer, lobular carcinoma, lung cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lymphoma-Hodgkin lymphoma, lymphoma-non-Hodgkin, malignant glioma, melanoma, meningioma, multiple myeloma, myelodysplastic syndrome (MDS), nasopharyngeal carcinoma, neuroendocrine tumors, oral cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors, parathyroid cancer, penile cancer, peritoneal cancer, Peutz-Jeghers syndrome, pituitary tumor, polycythemia vera, prostate cancer, renal cell carcinoma, retinoblastoma, salivary gland cancer, sarcoma, sarcoma-Kaposi, skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma, thyroid cancer, uterine (endometrial) cancer, vaginal cancer, and Wilms' tumor.
[0033] In some embodiments, the disease or condition is an inflammatory bowel disease, such as Crohn's disease (CD) or ulcerative colitis (UC). The subject may suffer from fibrosis, fibrostenosis, or fibrotic disease, either alone or in combination with an inflammatory disease. In some cases, the CD is severe CD. Severe CD results from inflammation, resulting in the formation of scar tissue (fibrostenosis) and / or swelling in the intestinal wall. In some cases, severe CD is characterized by the presence of fibrotic and / or inflammatory strictures. Strictures may be determined by computed tomography enterography (CTE) and magnetic resonance imaging enterography (MRE). The disease or condition may be characterized as refractory, which in some cases means that the disease is resistant to standard treatment (e.g., anti-TNF-α therapy). Non-limiting examples of standard therapies include glucocorticosteroids, anti-TNF therapy, anti-a4-b7 therapy (vedolizumab), anti-IL12p40 therapy (ustekinumab), thalidomide, and cytoxin.
[0034] Genetic types Genotypes are disclosed herein, and can be determined in a sample obtained from a subject by analyzing the genetic material in the sample. In some examples, the subject may be a human. In some embodiments, the genetic material is obtained from a subject with a disease or condition disclosed herein. In some examples, the genetic material is obtained from blood, serum, plasma, sweat, hair, tears, urine, and other techniques known to those skilled in the art. In some examples, the genetic material is obtained by biopsy, for example, from the intestinal tract of a subject.
[0035] The genotype of the present disclosure includes genetic material that is deoxyribonucleic acid (DNA). In some examples, the genotype includes denatured DNA molecules or fragments thereof. In some examples, the genotype includes DNA selected from genomic DNA, viral DNA, mitochondrial DNA, plasmid DNA, amplified DNA, circular DNA, circulating DNA, cell-free DNA, or exosomal DNA. In some examples, the DNA is single-stranded DNA (ssDNA), double-stranded DNA, denatured double-stranded DNA, synthetic DNA, and combinations thereof. The circular DNA may be cut or fragmented.
[0036] The genotypes disclosed herein include at least one polymorphism in a gene or at a locus described herein. In some instances, the gene or locus is Tumor Necrosis Factor (Ligand) Superfamily, Member 15 (TNFSF15), THADA Armadillo Repeat Containing (THADA), Pleckstrin Homology, MyTH4 And FERM Domain Containing H2 (PLEKHH2), XK Related 6 (XKR6), Myotubularin Related Protein 9 (MTMR9), ETS Proto-Oncogene 1 Transcription Factor (ETS1), C-Type Lectin Domain Containing 16A (CLEC16A), Suppressor Of Cytokine Signaling 1 (SOCS1), Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2), Inducible T Cell Coactivator Ligand (ICOSLG), Janus Kinase 2 (JAK2), Catenin Delta 2 (CTNND2), Regulator Of G Protein Signaling 7 (RGS7), RNA Binding Fox-1 Homolog 1 (RBFOX1), RNA Binding Motif Protein 17 (RBM17), 6-Phosphofructo-2-Kinase / Fructose-2,6-Biphosphatase 3 (PFKFB3), Ecto-NOX Disulfide-Thiol Exchanger 1 (ENOX1), Coiled-Coil Domain Containing 122 (CCDC122), Regulator Of Telomere Elongation Helicase 1 (RTEL1), TNF Receptor Superfamily Member 6b (TNFRSF6B), GLIS Family Zinc Finger 3 (GLIS3), Solute Carrier Family 1 Member 1 (SLC1A1), IKAROS Family Zinc Finger 2 (IKZF2), Fatty Acyl-CoA Reductase 1 (FAR1), Spondin 1(SPON1), Plexin A2 (PLXNA2), MIR205 Host Gene (MIR205HG), C-Type Lectin Domain Containing 16A (CLEC16A), PR / SET Domain 14 (PRDM), Autophagy Related 5 (ATG5), and Prostaglandin E Receptor 4 (PTGER4). In some examples, the gene or locus includes a gene or locus provided in Table 1. The genotypes disclosed herein are, in some examples, haplotypes. In some examples, the genotypes include specific polymorphisms, polymorphisms in linkage disequilibrium (LD) therewith, or combinations thereof. In some examples, LD is defined by an r2 of at least or about 0.70, 0.75, 0.80, 0.85, 0.90, or 1.0. The genotypes disclosed herein can include at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more polymorphisms. In a preferred embodiment, the genotypes disclosed herein include a combination of three polymorphisms, such as those provided in Table 1.
[0037] The polymorphisms described herein may be single nucleotide polymorphisms or indels (insertion / deletion). In some examples, the polymorphism is an insertion or deletion (e.g., indel) of at least one nucleic acid base. In some examples, the genotype may include copy number variation (CNV). The polymorphism is a variation in the number of nucleic acid sequences between individuals in a given population. In some examples, the CNV comprises at least or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 nucleic acid molecules. In some examples, the genotype is heterozygous. In some examples, the genotype is homozygous.
[0038] In the following embodiments, the following genotypes disclosed herein are disclosed: 1. A genotype that includes at least one polymorphism in a gene or locus. 2. The genotype of embodiment 1, comprising the polymorphisms provided in Table 1. 3. The genotype according to embodiments 1-2, being heterozygous. 4. The genotype according to embodiments 1-2, being homozygous. 5. The genotype according to embodiments 1 to 4, wherein the genotype comprises at least two polymorphisms. 6. The genotype of embodiments 1 to 4, wherein the genotype comprises at least three polymorphisms. 7. The genotype of embodiments 1 to 4, wherein the genotype comprises at least four polymorphisms. 8. The genotype of embodiments 1 to 4, wherein the genotype comprises at least five polymorphisms. 9. The genotype of embodiments 1 to 4, wherein the genotype comprises at least six polymorphisms. 10. The genotype of embodiments 1 to 4, wherein the genotype comprises at least seven polymorphisms. 11. The genotype of embodiments 1 to 4, wherein the genotype comprises at least eight polymorphisms. 12. The genotype of embodiment 1, comprising a polymorphism in linkage disequilibrium with the polymorphisms provided in Table 1. 13. The genotype of embodiment 12, wherein LD is defined as (i) a D' value of at least about 0.70, or (ii) a D' value of 0 and an r2 value of at least about 0.70. 14. The genotype of embodiment 12, wherein LD is defined as (i) a D' value of at least about 0.80, or (ii) a D' value of 0 and an r2 value of at least about 0.80. 15. The genotype of embodiment 12, wherein LD is defined as (i) a D' value of at least about 0.90, or (ii) a D' value of 0 and an r2 value of at least about 0.90. 16. The genotype of embodiment 12, wherein LD is defined as (i) a D' value of at least about 0.95, or (ii) a D' value of 0 and an r2 value of at least about 0.95. 17. Tumor Necrosis Factor (Ligand) Superfamily, Member 15 (TNFSF15), THADA Armadillo Repeat Containing (THADA), Hom Strin and FERM Domain Containing H2 (PLEKHH2)、XK Related 6 (XKR6)、Myotubularin Related Protein 9 (MTMR9)、ETS Proto-Oncogene 1、Transcription Factor (ETS1)、C-Type Lectin Domain Containing 16A (OEC) Cytokine Signaling 1 (SOCS1)、Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2)、Inducible T Cell Costimulator Ligand (ICOSLG)、Janus Kinase 2 (JAK2)、Catenin Delta 2 (CTNND2) Signaling Protein G7 (RGS7)、RNA Binding Fox-1 Homolog 1 (RBFOX1)、RNA Binding Motif Protein 17 (RBM17)、6-Phosphofructo-2-Kinase / Fructose-2,6-Biphosphatase 3 (PFKFB3), Ecto-NOX Disulfide-Thiol Exchanger 1 (ENOX1), Coiled-Coil Domain Containing 122 (CCDC122), Regulator Of Telomere Elongation Helicase 1 (RTEL1), TNF Receptor Superfamily Member 6b (TNFRSF6B), GLIS Family Zinc Finger 3 (GLIS3), Solute Carrier Family 1 Member 1 (SLC1A1), IKAROS Family Zinc Finger 2 (IKZF2), Fatty Acyl-CoA Reductase 1 (FAR1), Spondin 1(SPON1), Plexin A2 (PLXNA2), MIR205 Host Gene (MIR205HG), C-Type Lectin Domain Containing 16A (CLEC16A), PR / SET Domain 14 The genotype described in embodiments 1 to 16 is selected from the group consisting of PRDM, Autophagy Related 5 (ATG5), and Prostaglandin E Receptor 4 (PTGER4). 18. The genotype of embodiments 5-6, wherein the genotype comprises at least two polymorphisms selected from: (1) rs16901748, rs7759385, rs4246905; (2) rs16901748, rs7759385, rs7935393; (3) rs16901748, rs7759385, rs1892231; (4) rs16901748, rs7759385, rs12934476; (5) rs16901748, rs7759385, rs9806914; (6) rs16901748, rs7759385, rs2297437; (7) rs16901748, rs7759385, rs2070557; (8) rs16901748、rs7759385、rs7278257; (9) rs16901748、rs7759385、rs11221332; (10) rs16901748、rs7759385、rs41309367; (11) rs16901748、rs7759385、rs6478109; (12) rs16901748、rs4246905、rs7935393; (13) rs16901748、rs4246905、rs1892231; (14) rs16901748、rs4246905、rs12934476; (15) rs16901748、rs4246905、rs9806914; (16) rs16901748、rs4246905、rs2297437; (17) rs16901748、rs4246905、rs2070557; (18) rs16901748、rs4246905、rs7278257; (19) rs16901748、rs4246905、rs11221332; (20) rs16901748、rs4246905、rs41309367; (21) rs16901748、rs4246905、rs6478109; (22) rs16901748、rs7935393、rs1892231; (23) rs16901748、rs7935393、rs12934476; (24) rs16901748、rs7935393、rs9806914; (25) rs16901748、rs7935393、rs2297437; (26) rs16901748、rs7935393、rs2070557; (27) rs16901748、rs7935393、rs7278257; (28) rs16901748、rs7935393、rs11221332; (29) rs16901748、rs7935393、rs41309367; (30) rs16901748、rs7935393、rs6478109; (31) rs16901748、rs1892231、rs12934476; (32) rs16901748、rs1892231、rs9806914; (33) rs16901748、rs1892231、rs2297437; (34) rs16901748、rs1892231、rs2070557; (35) rs16901748、rs1892231、rs7278257; (36) rs16901748、rs1892231、rs11221332; (37) rs16901748、rs1892231、rs41309367; (38) rs16901748、rs1892231、rs6478109; (39) rs16901748、rs12934476、rs9806914; (40) rs16901748、rs12934476、rs2297437; (41) rs16901748、rs12934476、rs2070557; (42) rs16901748、rs12934476、rs7278257; (43) rs16901748、rs12934476、rs11221332; (44) rs16901748、rs12934476、rs41309367; (45) rs16901748、rs12934476、rs6478109; (46) rs16901748、rs9806914、rs2297437; (47) rs16901748、rs9806914、rs2070557; (48) rs16901748、rs9806914、rs7278257; (49) rs16901748、rs9806914、rs11221332; (50) rs16901748、rs9806914、rs41309367; (51) rs16901748、rs9806914、rs6478109; (52) rs16901748、rs2297437、rs2070557; (53) rs16901748、rs2297437、rs7278257; (54) rs16901748、rs2297437、rs11221332; (55) rs16901748、rs2297437、rs41309367; (56) rs16901748、rs2297437、rs6478109; (57) rs16901748、rs2070557、rs7278257; (58) rs16901748、rs2070557、rs11221332; (59) rs16901748、rs2070557、rs41309367; (60) rs16901748、rs2070557、rs6478109; (61) rs16901748、rs7278257、rs11221332; (62) rs16901748、rs7278257、rs41309367; (63) rs16901748、rs7278257、rs6478109; (64) rs16901748、rs11221332、rs41309367; (65) rs16901748、rs11221332、rs6478109; (66) rs16901748、rs41309367、rs6478109; (67) rs7759385、rs4246905、rs7935393; (68) rs7759385, rs4246905, rs1892231; (69) rs7759385, rs4246905, rs12934476; (70) rs7759385, rs4246905, rs9806914; (71) rs7759385, rs4246905, rs2297437; (72) rs7759385, rs4246905, rs2070557; (73) rs7759385, rs4246905, rs7278257; (74) rs7759385, rs4246905, rs11221332; (75) rs7759385, rs4246905, rs41309367; (76) rs7759385, rs4246905, rs6478109; (77) rs7759385, rs7935393, rs1892231; (78) rs7759385, rs7935393, rs12934476; (79) rs7759385, rs7935393, rs9806914; (80) rs7759385, rs7935393, rs2297437; (81) rs7759385, rs7935393, rs2070557; (82) rs7759385, rs7935393, rs7278257; (83) rs7759385, rs7935393, rs11221332; (84) rs7759385, rs7935393, rs41309367; (85) rs7759385, rs7935393, rs6478109; (86) rs7759385, rs1892231, rs12934476; (87) rs7759385, rs1892231, rs9806914; (88) rs7759385, rs1892231, rs2297437; (89) rs7759385, rs1892231, rs2070557; (90) rs7759385, rs1892231, rs7278257; (91) rs7759385, rs1892231, rs11221332; (92) rs7759385, rs1892231, rs41309367; (93) rs7759385, rs1892231, rs6478109; (94) rs7759385, rs12934476, rs9806914; (95) rs7759385, rs12934476, rs2297437; (96) rs7759385, rs12934476, rs2070557; (97) rs7759385, rs12934476, rs7278257; (98) rs7759385, rs12934476, rs11221332; (99) rs7759385, rs12934476, rs41309367; (100) rs7759385, rs12934476, rs6478109; (101) rs7759385, rs9806914, rs2297437; (102) rs7759385, rs9806914, rs2070557; (103) rs7759385, rs9806914, rs7278257; (104) rs7759385, rs9806914, rs11221332; (105) rs7759385, rs9806914, rs41309367; (106) rs7759385, rs9806914, rs6478109; (107) rs7759385, rs2297437, rs2070557; (108) rs7759385, rs2297437, rs7278257; (109) rs7759385, rs2297437, rs11221332; (110) rs7759385, rs2297437, rs41309367; (111) rs7759385, rs2297437, rs6478109; (112) rs7759385, rs2070557, rs7278257; (113) rs7759385, rs2070557, rs11221332; (114) rs7759385, rs2070557, rs41309367; (115) rs7759385, rs2070557, rs6478109; (116) rs7759385, rs7278257, rs11221332; (117) rs7759385, rs7278257, rs41309367; (118) rs7759385, rs7278257, rs6478109; (119) rs7759385, rs11221332, rs41309367; (120) rs7759385, rs11221332, rs6478109; (121) rs7759385, rs41309367, rs6478109; (122) rs4246905, rs7935393, rs1892231; (123) rs4246905, rs7935393, rs12934476; (124) rs4246905, rs7935393, rs9806914; (125) rs4246905, rs7935393, rs2297437; (126) rs4246905, rs7935393, rs2070557; (127) rs4246905, rs7935393, rs7278257; (128) rs4246905、rs7935393、rs11221332; (129) rs4246905、rs7935393、rs41309367; (130) rs4246905、rs7935393、rs6478109; (131) rs4246905、rs1892231、rs12934476; (132) rs4246905、rs1892231、rs9806914; (133) rs4246905、rs1892231、rs2297437; (134) rs4246905、rs1892231、rs2070557; (135) rs4246905、rs1892231、rs7278257; (136) rs4246905、rs1892231、rs11221332; (137) rs4246905、rs1892231、rs41309367; (138) rs4246905、rs1892231、rs6478109; (139) rs4246905、rs12934476、rs9806914; (140) rs4246905、rs12934476、rs2297437; (141) rs4246905、rs12934476、rs2070557; (142) rs4246905、rs12934476、rs7278257; (143) rs4246905、rs12934476、rs11221332; (144) rs4246905、rs12934476、rs41309367; (145) rs4246905、rs12934476、rs6478109; (146) rs4246905、rs9806914、rs2297437; (147) rs4246905、rs9806914、rs2070557; (148) rs4246905、rs9806914、rs7278257; (149) rs4246905、rs9806914、rs11221332; (150) rs4246905、rs9806914、rs41309367; (151) rs4246905、rs9806914、rs6478109; (152) rs4246905、rs2297437、rs2070557; (153) rs4246905、rs2297437、rs7278257; (154) rs4246905、rs2297437、rs11221332; (155) rs4246905、rs2297437、rs41309367; (156) rs4246905、rs2297437、rs6478109; (157) rs4246905、rs2070557、rs7278257; (158) rs4246905、rs2070557、rs11221332; (159) rs4246905、rs2070557、rs41309367; (160) rs4246905、rs2070557、rs6478109; (161) rs4246905、rs7278257、rs11221332; (162) rs4246905、rs7278257、rs41309367; (163) rs4246905、rs7278257、rs6478109; (164) rs4246905、rs11221332、rs41309367; (165) rs4246905、rs11221332、rs6478109; (166) rs4246905、rs41309367、rs6478109; (167) rs7935393、rs1892231、rs12934476; (168) rs7935393, rs1892231, rs9806914; (169) rs7935393, rs1892231, rs2297437; (170) rs7935393, rs1892231, rs2070557; (171) rs7935393, rs1892231, rs7278257; (172) rs7935393, rs1892231, rs11221332; (173) rs7935393, rs1892231, rs41309367; (174) rs7935393, rs1892231, rs6478109; (175) rs7935393, rs12934476, rs9806914; (176) rs7935393, rs12934476, rs2297437; (177) rs7935393, rs12934476, rs2070557; (178) rs7935393, rs12934476, rs7278257; (179) rs7935393, rs12934476, rs11221332; (180) rs7935393, rs12934476, rs41309367; (181) rs7935393, rs12934476, rs6478109; (182) rs7935393, rs9806914, rs2297437; (183) rs7935393, rs9806914, rs2070557; (184) rs7935393, rs9806914, rs7278257; (185) rs7935393, rs9806914, rs11221332; (186) rs7935393, rs9806914, rs41309367; (187) rs7935393, rs9806914, rs6478109; (188) rs7935393, rs2297437, rs2070557; (189) rs7935393, rs2297437, rs7278257; (190) rs7935393, rs2297437, rs11221332; (191) rs7935393, rs2297437, rs41309367; (192) rs7935393, rs2297437, rs6478109; (193) rs7935393, rs2070557, rs7278257; (194) rs7935393, rs2070557, rs11221332; (195) rs7935393, rs2070557, rs41309367; (196) rs7935393, rs2070557, rs6478109; (197) rs7935393, rs7278257, rs11221332; (198) rs7935393, rs7278257, rs41309367; (199) rs7935393, rs7278257, rs6478109; (200) rs7935393, rs11221332, rs4130936;7 (201) rs7935393, rs11221332, rs6478109; (202) rs7935393, rs41309367, rs6478109; (203) rs1892231、rs12934476、rs9806914; (204) rs1892231、rs12934476、rs2297437; (205) rs1892231、rs12934476、rs2070557; (206) rs1892231, rs12934476, rs7278257; (207) rs1892231、rs12934476、rs11221332; (208) rs1892231、rs12934476、rs41309367; (209) rs1892231、rs12934476、rs6478109; (210) rs1892231、rs9806914、rs2297437; (211) rs1892231、rs9806914、rs2070557; (212) rs1892231、rs9806914、rs7278257; (213) rs1892231、rs9806914、rs11221332; (214) rs1892231、rs9806914、rs41309367; (215) rs1892231、rs9806914、rs6478109; (216) rs1892231、rs2297437、rs2070557; (217) rs1892231、rs2297437、rs7278257; (218) rs1892231、rs2297437、rs11221332; (219) rs1892231、rs2297437、rs41309367; (220) rs1892231、rs2297437、rs6478109; (221) rs1892231、rs2070557、rs7278257; (222) rs1892231、rs2070557、rs11221332; (223) rs1892231、rs2070557、rs41309367; (224) rs1892231、rs2070557、rs6478109; (225) rs1892231、rs7278257、rs11221332; (226) rs1892231、rs7278257、rs41309367; (227) rs1892231、rs7278257、rs6478109; (228) rs1892231、rs11221332、rs41309367; (229) rs1892231、rs11221332、rs6478109; (230) rs1892231、rs41309367、rs6478109; (231) rs12934476、rs9806914、rs2297437; (232) rs12934476、rs9806914、rs2070557; (233) rs12934476、rs9806914、rs7278257; (234) rs12934476、rs9806914、rs11221332; (235) rs12934476、rs9806914、rs41309367; (236) rs12934476、rs9806914、rs6478109; (237) rs12934476、rs2297437、rs2070557; (238) rs12934476、rs2297437、rs7278257; (239) rs12934476、rs2297437、rs11221332; (240) rs12934476、rs2297437、rs41309367; (241) rs12934476、rs2297437、rs6478109; (242) rs12934476、rs2070557、rs7278257; (243) rs12934476、rs2070557、rs11221332; (244) rs12934476、rs2070557、rs41309367; (245) rs12934476、rs2070557、rs6478109; (246) rs12934476、rs7278257、rs11221332; (247) rs12934476、rs7278257、rs41309367; (248) rs12934476、rs7278257、rs6478109; (249) rs12934476、rs11221332、rs41309367; (250) rs12934476、rs11221332、rs6478109; (251) rs12934476、rs41309367、rs6478109; (252) rs9806914、rs2297437、rs2070557; (253) rs9806914、rs2297437、rs7278257; (254) rs9806914、rs2297437、rs11221332; (255) rs9806914、rs2297437、rs41309367; (256) rs9806914、rs2297437、rs6478109; (257) rs9806914、rs2070557、rs7278257; (258) rs9806914、rs2070557、rs11221332; (259) rs9806914、rs2070557、rs41309367; (260) rs9806914、rs2070557、rs6478109; (261) rs9806914、rs7278257、rs11221332; (262) rs9806914、rs7278257、rs41309367; (263) rs9806914、rs7278257、rs6478109; (264) rs9806914、rs11221332、rs41309367; (265) rs9806914、rs11221332、rs6478109; (266) rs9806914、rs41309367、rs6478109; (267) rs2297437、rs2070557、rs7278257; (268) rs2297437, rs2070557, rs11221332; (269) rs2297437, rs2070557, rs41309367; (270) rs2297437, rs2070557, rs6478109; (271) rs2297437, rs7278257, rs11221332; (272) rs2297437, rs7278257, rs41309367; (273) rs2297437, rs7278257, rs6478109; (274) rs2297437, rs11221332, rs41309367; (275) rs2297437, rs11221332, rs6478109; (276) rs2297437, rs41309367, rs6478109; (277) rs2070557, rs7278257, rs11221332; (278) rs2070557, rs7278257, rs41309367; (279) rs2070557, rs7278257, rs6478109; (280) rs2070557, rs11221332, rs41309367; (281) rs2070557, rs11221332, rs6478109; (282) rs2070557, rs41309367, rs6478109; (283) rs7278257, rs11221332, rs41309367; (284) rs7278257, rs11221332, rs6478109; (285) rs7278257, rs41309367, rs6478109; or (286) rs11221332, rs41309367, rs6478109. 19. The genotype of embodiment 18, wherein rs7278257 is replaced with rs56124762. 20. The genotype of embodiment 18, wherein rs7278257 is replaced with rs2070558. 21. The genotype described in embodiment 18, wherein rs7278257 is replaced with rs2070561. 22. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, imm_11_127948309, and rs1892231. 23. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, imm_11_127948309, and rs9806914. 24. The genotype described in embodiments 5-6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, imm_11_127948309, and imm_21_44478192. 25. The genotype described in embodiments 5-6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, imm_11_127948309, and imm_21_44479552. 26. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, rs1892231, and rs9806914. 27. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, rs1892231, and imm_21_44478192. 28. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, rs1892231, and imm_21_44479552. 29. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, rs9806914, and imm_21_44478192. 30. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, rs9806914, and imm_21_44479552. 31. The genotype described in embodiments 5-6, wherein the genotype comprises at least two polymorphisms selected from imm_9_116608587, imm_21_44478192, and imm_21_44479552. 32. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_11_127948309, rs1892231, and rs9806914. 33. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_11_127948309, rs1892231, and imm_21_44478192. 34. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_11_127948309, rs1892231, and imm_21_44479552. 35. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from imm_11_127948309, rs9806914, and imm_21_44478192. 36. The genotype described in embodiments 5-6, wherein the genotype comprises at least two polymorphisms selected from imm_11_127948309, rs9806914, and imm_21_44479552. 37. The genotype described in embodiments 5-6, wherein the genotype comprises at least two polymorphisms selected from imm_11_127948309, imm_21_44478192, and imm_21_44479552. 38. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs1892231, rs9806914, and imm_21_44478192. 39. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs1892231, rs9806914, and imm_21_44479552. 40. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs1892231, imm_21_44478192, and imm_21_44479552. 41. The genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs9806914, imm_21_44478192, and imm_21_44479552. 42. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs56124762, and rs1892231. 43. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs56124762, and rs16901748. 44. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs1892231, and rs16901748. 45. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs56124762, rs1892231, and rs16901748. 46. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs2070558, and rs1892231. 47. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs2070558, and rs16901748. 48. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs1892231, and rs16901748. 49. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs2070558, rs1892231, and rs16901748. 50. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs2070561, and rs1892231. 51. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs2070561, and rs16901748. 52. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs6478109, rs1892231, and rs16901748. 53. A genotype described in embodiments 5 to 6, wherein the genotype comprises at least two polymorphisms selected from rs2070561, rs1892231, and rs16901748. 54. The genotype of embodiment 11, wherein the genotype comprises eight polymorphisms selected from the following: (1) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs9806914, rs2297437 (2) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs9806914, rs1326860 (3) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs9806914, rs12457255 (4) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs9806914, rs2815844 (5) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs9806914, rs10974900 (6) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs9806914、rs2409750 (7) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs9806914、rs1541020 (8) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs9806914、rs4942248 (9) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs9806914、rs7759385 (10) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs1326860 (11) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs12457255 (12) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs2815844 (13) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs10974900 (14) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs2409750 (15) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs1541020 (16) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs4942248 (17) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2297437、rs7759385 (18) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs12457255 (19) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs2815844 (20) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs10974900 (21) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs2409750 (22) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs1541020 (23) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs4942248 (24) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1326860、rs7759385 (25) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs12457255、rs2815844 (26) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs12457255、rs10974900 (27) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs12457255、rs2409750 (28) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs12457255、rs1541020 (29) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs12457255、rs4942248 (30) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs12457255、rs7759385 (31) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2815844、rs10974900 (32) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2815844、rs2409750 (33) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2815844、rs1541020 (34) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2815844、rs4942248 (35) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2815844、rs7759385 (36) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs10974900、rs2409750 (37) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs10974900、rs1541020 (38) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs10974900、rs4942248 (39) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs10974900、rs7759385 (40) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2409750、rs1541020 (41) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2409750、rs4942248 (42) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs2409750、rs7759385 (43) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1541020、rs4942248 (44) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs1541020、rs7759385 (45) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs7935393、rs4942248、rs7759385 (46) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs1326860 (47) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs12457255 (48) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs2815844 (49) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs10974900 (50) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs2409750 (51) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs1541020 (52) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs4942248 (53) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2297437、rs7759385 (54) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs12457255 (55) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs2815844 (56) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs10974900 (57) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs2409750 (58) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs1541020 (59) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs4942248 (60) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1326860、rs7759385 (61) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs12457255、rs2815844 (62) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs12457255、rs10974900 (63) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs12457255、rs2409750 (64) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs12457255、rs1541020 (65) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs12457255、rs4942248 (66) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs12457255、rs7759385 (67) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2815844、rs10974900 (68) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2815844、rs2409750 (69) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2815844、rs1541020 (70) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2815844、rs4942248 (71) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2815844、rs7759385 (72) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs10974900、rs2409750 (73) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs10974900、rs1541020 (74) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs10974900、rs4942248 (75) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs10974900、rs7759385 (76) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2409750、rs1541020 (77) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2409750、rs4942248 (78) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs2409750、rs7759385 (79) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1541020、rs4942248 (80) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs1541020、rs7759385 (81) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs9806914、rs4942248、rs7759385 (82) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs12457255 (83) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs2815844 (84) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs10974900 (85) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs2409750 (86) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs1541020 (87) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs4942248 (88) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1326860、rs7759385 (89) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs12457255、rs2815844 (90) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs12457255、rs10974900 (91) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs12457255、rs2409750 (92) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs12457255、rs1541020 (93) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs12457255、rs4942248 (94) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs12457255、rs7759385 (95) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2815844、rs10974900 (96) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2815844、rs2409750 (97) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2815844、rs1541020 (98) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2815844、rs4942248 (99) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2815844、rs7759385 (100) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs10974900、rs2409750 (101) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs10974900、rs1541020 (102) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs10974900、rs4942248 (103) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs10974900、rs7759385 (104) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2409750、rs1541020 (105) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2409750、rs4942248 (106) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs2409750、rs7759385 (107) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1541020、rs4942248 (108) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs1541020、rs7759385 (109) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2297437、rs4942248、rs7759385 (110) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs12457255、rs2815844 (111) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs12457255、rs10974900 (112) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs12457255、rs2409750 (113) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs12457255、rs1541020 (114) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs12457255、rs4942248 (115) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs12457255、rs7759385 (116) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2815844、rs10974900 (117) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2815844、rs2409750 (118) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2815844、rs1541020 (119) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2815844、rs4942248 (120) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2815844、rs7759385 (121) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs10974900、rs2409750 (122) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs10974900、rs1541020 (123) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs10974900、rs4942248 (124) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs10974900、rs7759385 (125) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2409750、rs1541020 (126) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2409750、rs4942248 (127) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs2409750、rs7759385 (128) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs1541020、rs4942248 (129) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs1541020、rs7759385 (130) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1326860、rs4942248、rs7759385 (131) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2815844、rs10974900 (132) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2815844、rs2409750 (133) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2815844、rs1541020 (134) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2815844、rs4942248 (135) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2815844、rs7759385 (136) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs10974900、rs2409750 (137) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs10974900、rs1541020 (138) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs10974900、rs4942248 (139) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs10974900、rs7759385 (140) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2409750、rs1541020 (141) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2409750、rs4942248 (142) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs2409750、rs7759385 (143) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs1541020、rs4942248 (144) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs1541020、rs7759385 (145) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs12457255、rs4942248、rs7759385 (146) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs10974900、rs2409750 (147) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs10974900、rs1541020 (148) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs10974900、rs4942248 (149) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs10974900、rs7759385 (150) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs2409750、rs1541020 (151) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs2409750、rs4942248 (152) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs2409750、rs7759385 (153) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs1541020、rs4942248 (154) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs1541020、rs7759385 (155) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2815844、rs4942248、rs7759385 (156) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs10974900、rs2409750、rs1541020 (157) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs10974900、rs2409750、rs4942248 (158) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs10974900、rs2409750、rs7759385 (159) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs10974900、rs1541020、rs4942248 (160) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs10974900、rs1541020、rs7759385 (161) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs10974900、rs4942248、rs7759385 (162) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2409750、rs1541020、rs4942248 (163) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2409750、rs1541020、rs7759385 (164) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs2409750、rs4942248、rs7759385 (165) rs6478109、rs56124762、rs1892231、rs16901748、rs12934476、rs1541020、rs4942248、rs7759385 (166) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs1326860 (167) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs12457255 (168) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs2815844 (169) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs10974900 (170) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs2409750 (171) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs1541020 (172) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs4942248 (173) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2297437、rs7759385 (174) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs12457255 (175) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs2815844 (176) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs10974900 (177) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs2409750 (178) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs1541020 (179) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs4942248 (180) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1326860、rs7759385 (181) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs12457255、rs2815844 (182) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs12457255、rs10974900 (183) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs12457255、rs2409750 (184) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs12457255、rs1541020 (185) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs12457255、rs4942248 (186) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs12457255、rs7759385 (187) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2815844、rs10974900 (188) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2815844、rs2409750 (189) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2815844、rs1541020 (190) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2815844、rs4942248 (191) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2815844、rs7759385 (192) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs10974900、rs2409750 (193) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs10974900、rs1541020 (194) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs10974900、rs4942248 (195) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs10974900、rs7759385 (196) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2409750、rs1541020 (197) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2409750、rs4942248 (198) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs2409750、rs7759385 (199) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1541020、rs4942248 (200) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs1541020、rs7759385 (201) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs9806914、rs4942248、rs7759385 (202) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs12457255 (203) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs2815844 (204) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs10974900 (205) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs2409750 (206) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs1541020 (207) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs4942248 (208) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1326860、rs7759385 (209) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs12457255、rs2815844 (210) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs12457255、rs10974900 (211) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs12457255、rs2409750 (212) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs12457255、rs1541020 (213) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs12457255、rs4942248 (214) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs12457255、rs7759385 (215) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2815844、rs10974900 (216) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2815844、rs2409750 (217) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2815844、rs1541020 (218) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2815844、rs4942248 (219) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2815844、rs7759385 (220) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs10974900、rs2409750 (221) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs10974900、rs1541020 (222) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs10974900、rs4942248 (223) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs10974900、rs7759385 (224) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2409750、rs1541020 (225) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2409750、rs4942248 (226) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs2409750、rs7759385 (227) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1541020、rs4942248 (228) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs1541020、rs7759385 (229) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2297437、rs4942248、rs7759385 (230) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs12457255、rs2815844 (231) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs12457255、rs10974900 (232) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs12457255、rs2409750 (233) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs12457255、rs1541020 (234) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs12457255、rs4942248 (235) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs12457255、rs7759385 (236) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2815844、rs10974900 (237) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2815844、rs2409750 (238) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2815844、rs1541020 (239) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2815844、rs4942248 (240) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2815844、rs7759385 (241) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs10974900、rs2409750 (242) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs10974900、rs1541020 (243) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs10974900、rs4942248 (244) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs10974900、rs7759385 (245) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2409750、rs1541020 (246) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2409750、rs4942248 (247) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs2409750、rs7759385 (248) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs1541020、rs4942248 (249) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs1541020、rs7759385 (250) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1326860、rs4942248、rs7759385 (251) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2815844、rs10974900 (252) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2815844、rs2409750 (253) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2815844、rs1541020 (254) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2815844、rs4942248 (255) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2815844、rs7759385 (256) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs10974900、rs2409750 (257) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs10974900、rs1541020 (258) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs10974900、rs4942248 (259) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs10974900、rs7759385 (260) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2409750、rs1541020 (261) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2409750、rs4942248 (262) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs2409750、rs7759385 (263) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs1541020、rs4942248 (264) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs1541020、rs7759385 (265) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs12457255、rs4942248、rs7759385 (266) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs10974900、rs2409750 (267) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs10974900、rs1541020 (268) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs10974900、rs4942248 (269) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs10974900、rs7759385 (270) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs2409750、rs1541020 (271) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs2409750、rs4942248 (272) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs2409750、rs7759385 (273) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs1541020、rs4942248 (274) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs1541020、rs7759385 (275) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2815844、rs4942248、rs7759385 (276) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs10974900、rs2409750、rs1541020 (277) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs10974900、rs2409750、rs4942248 (278) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs10974900、rs2409750、rs7759385 (279) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs10974900、rs1541020、rs4942248 (280) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs10974900、rs1541020、rs7759385 (281) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs10974900、rs4942248、rs7759385 (282) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2409750、rs1541020、rs4942248 (283) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2409750、rs1541020、rs7759385 (284) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs2409750、rs4942248、rs7759385 (285) rs6478109、rs56124762、rs1892231、rs16901748、rs7935393、rs1541020、rs4942248、rs7759385 (286) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs12457255 (287) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs2815844 (288) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs10974900 (289) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs2409750 (290) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs1541020 (291) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs4942248 (292) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1326860、rs7759385 (293) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs12457255、rs2815844 (294) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs12457255、rs10974900 (295) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs12457255、rs2409750 (296) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs12457255、rs1541020 (297) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs12457255、rs4942248 (298) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs12457255、rs7759385 (299) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2815844、rs10974900 (300) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2815844、rs2409750 (301) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2815844、rs1541020 (302) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2815844、rs4942248 (303) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2815844、rs7759385 (304) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs10974900、rs2409750 (305) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs10974900、rs1541020 (306) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs10974900、rs4942248 (307) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs10974900、rs7759385 (308) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2409750、rs1541020 (309) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2409750、rs4942248 (310) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs2409750、rs7759385 (311) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1541020、rs4942248 (312) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs1541020、rs7759385 (313) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2297437、rs4942248、rs7759385 (314) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs12457255、rs2815844 (315) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs12457255、rs10974900 (316) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs12457255、rs2409750 (317) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs12457255、rs1541020 (318) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs12457255、rs4942248 (319) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs12457255、rs7759385 (320) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2815844、rs10974900 (321) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2815844、rs2409750 (322) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2815844、rs1541020 (323) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2815844、rs4942248 (324) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2815844、rs7759385 (325) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs10974900、rs2409750 (326) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs10974900、rs1541020 (327) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs10974900、rs4942248 (328) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs10974900、rs7759385 (329) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2409750、rs1541020 (330) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2409750、rs4942248 (331) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs2409750、rs7759385 (332) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs1541020、rs4942248 (333) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs1541020、rs7759385 (334) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1326860、rs4942248、rs7759385 (335) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2815844、rs10974900 (336) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2815844、rs2409750 (337) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2815844、rs1541020 (338) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2815844、rs4942248 (339) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2815844、rs7759385 (340) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs10974900、rs2409750 (341) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs10974900、rs1541020 (342) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs10974900、rs4942248 (343) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs10974900、rs7759385 (344) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2409750、rs1541020 (345) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2409750、rs4942248 (346) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs2409750、rs7759385 (347) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs1541020、rs4942248 (348) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs1541020、rs7759385 (349) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs12457255、rs4942248、rs7759385 (350) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs10974900、rs2409750 (351) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs10974900、rs1541020 (352) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs10974900、rs4942248 (353) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs10974900、rs7759385 (354) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs2409750、rs1541020 (355) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs2409750、rs4942248 (356) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs2409750、rs7759385 (357) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs1541020、rs4942248 (358) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs1541020、rs7759385 (359) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2815844、rs4942248、rs7759385 (360) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs10974900、rs2409750、rs1541020 (361) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs10974900、rs2409750、rs4942248 (362) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs10974900、rs2409750、rs7759385 (363) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs10974900、rs1541020、rs4942248 (364) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs10974900、rs1541020、rs7759385 (365) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs10974900、rs4942248、rs7759385 (366) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2409750、rs1541020、rs4942248 (367) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2409750、rs1541020、rs7759385 (368) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs2409750、rs4942248、rs7759385 (369) rs6478109、rs56124762、rs1892231、rs16901748、rs9806914、rs1541020、rs4942248、rs7759385 (370) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs12457255、rs2815844 (371) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs12457255、rs10974900 (372) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs12457255、rs2409750 (373) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs12457255、rs1541020 (374) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs12457255、rs4942248 (375) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs12457255、rs7759385 (376) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2815844、rs10974900 (377) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2815844、rs2409750 (378) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2815844、rs1541020 (379) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2815844、rs4942248 (380) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2815844、rs7759385 (381) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs10974900、rs2409750 (382) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs10974900、rs1541020 (383) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs10974900、rs4942248 (384) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs10974900、rs7759385 (385) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2409750、rs1541020 (386) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2409750、rs4942248 (387) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs2409750、rs7759385 (388) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs1541020、rs4942248 (389) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs1541020、rs7759385 (390) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1326860、rs4942248、rs7759385 (391) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2815844、rs10974900 (392) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2815844、rs2409750 (393) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2815844、rs1541020 (394) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2815844、rs4942248 (395) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2815844、rs7759385 (396) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs10974900、rs2409750 (397) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs10974900、rs1541020 (398) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs10974900、rs4942248 (399) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs10974900、rs7759385 (400) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2409750、rs1541020 (401) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2409750、rs4942248 (402) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs2409750、rs7759385 (403) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs1541020、rs4942248 (404) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs1541020、rs7759385 (405) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs12457255、rs4942248、rs7759385 (406) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs10974900、rs2409750 (407) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs10974900、rs1541020 (408) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs10974900、rs4942248 (409) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs10974900、rs7759385 (410) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs2409750、rs1541020 (411) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs2409750、rs4942248 (412) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs2409750、rs7759385 (413) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs1541020、rs4942248 (414) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs1541020、rs7759385 (415) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2815844、rs4942248、rs7759385 (416) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs10974900、rs2409750、rs1541020 (417) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs10974900、rs2409750、rs4942248 (418) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs10974900、rs2409750、rs7759385 (419) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs10974900、rs1541020、rs4942248 (420) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs10974900、rs1541020、rs7759385 (421) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs10974900、rs4942248、rs7759385 (422) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2409750、rs1541020、rs4942248 (423) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2409750、rs1541020、rs7759385 (424) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs2409750、rs4942248、rs7759385 (425) rs6478109、rs56124762、rs1892231、rs16901748、rs2297437、rs1541020、rs4942248、rs7759385 (426) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2815844、rs10974900 (427) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2815844、rs2409750 (428) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2815844、rs1541020 (429) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2815844、rs4942248 (430) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2815844、rs7759385 (431) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs10974900、rs2409750 (432) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs10974900、rs1541020 (433) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs10974900、rs4942248 (434) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs10974900、rs7759385 (435) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2409750、rs1541020 (436) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2409750、rs4942248 (437) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs2409750、rs7759385 (438) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs1541020、rs4942248 (439) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs1541020、rs7759385 (440) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs12457255、rs4942248、rs7759385 (441) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs10974900、rs2409750 (442) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs10974900、rs1541020 (443) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs10974900、rs4942248 (444) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs10974900、rs7759385 (445) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs2409750、rs1541020 (446) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs2409750、rs4942248 (447) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs2409750、rs7759385 (448) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs1541020、rs4942248 (449) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs1541020、rs7759385 (450) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2815844、rs4942248、rs7759385 (451) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs10974900、rs2409750、rs1541020 (452) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs10974900、rs2409750、rs4942248 (453) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs10974900、rs2409750、rs7759385 (454) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs10974900、rs1541020、rs4942248 (455) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs10974900、rs1541020、rs7759385 (456) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs10974900、rs4942248、rs7759385 (457) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2409750、rs1541020、rs4942248 (458) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2409750、rs1541020、rs7759385 (459) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs2409750、rs4942248、rs7759385 (460) rs6478109、rs56124762、rs1892231、rs16901748、rs1326860、rs1541020、rs4942248、rs7759385 (461) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs10974900、rs2409750 (462) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs10974900、rs1541020 (463) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs10974900、rs4942248 (464) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs10974900、rs7759385 (465) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs2409750、rs1541020 (466) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs2409750、rs4942248 (467) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs2409750、rs7759385 (468) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs1541020、rs4942248 (469) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs1541020、rs7759385 (470) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2815844、rs4942248、rs7759385 (471) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs10974900、rs2409750、rs1541020 (472) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs10974900、rs2409750、rs4942248 (473) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs10974900、rs2409750、rs7759385 (474) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs10974900、rs1541020、rs4942248 (475) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs10974900、rs1541020、rs7759385 (476) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs10974900、rs4942248、rs7759385 (477) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2409750、rs1541020、rs4942248 (478) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2409750、rs1541020、rs7759385 (479) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs2409750、rs4942248、rs7759385 (480) rs6478109、rs56124762、rs1892231、rs16901748、rs12457255、rs1541020、rs4942248、rs7759385 (481) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs10974900、rs2409750、rs1541020 (482) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs10974900、rs2409750、rs4942248 (483) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs10974900、rs2409750、rs7759385 (484) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs10974900、rs1541020、rs4942248 (485) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs10974900、rs1541020、rs7759385 (486) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs10974900、rs4942248、rs7759385 (487) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs2409750、rs1541020、rs4942248 (488) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs2409750、rs1541020、rs7759385 (489) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs2409750、rs4942248、rs7759385 (490) rs6478109、rs56124762、rs1892231、rs16901748、rs2815844、rs1541020、rs4942248、rs7759385 (491) rs6478109、rs56124762、rs1892231、rs16901748、rs10974900、rs2409750、rs1541020、rs4942248 (492) rs6478109, rs56124762, rs1892231, rs16901748, rs10974900, rs2409750, rs1541020, rs7759385 (493) rs6478109, rs56124762, rs1892231, rs16901748, rs10974900, rs2409750, rs4942248, rs7759385 (494) rs6478109, rs56124762, rs1892231, rs16901748, rs10974900, rs1541020, rs4942248, rs7759385 (495) rs6478109, rs56124762, rs1892231, rs16901748, rs2409750, rs1541020, rs4942248, rs7759385 55. The genotype described in embodiments 1 to 53, wherein the genotype, for at least one polymorphism, comprises a minor allele provided in Table 1. 56. The genotype described in embodiments 1 to 53, wherein the genotype, for at least one polymorphism, comprises a major allele provided in Table 1. 57. A genotype described in embodiments 1 to 56, wherein the presence of the genotype predicts a positive therapeutic response to treatment with an inhibitor of TL1A activity or expression with a positive predictive value of at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. 58. A genotype described in embodiments 1 to 57, wherein the presence of the genotype predicts a positive therapeutic response to treatment with an inhibitor of TL1A activity or expression with a specificity of at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
[0039] Embodiments disclosed herein provide genotypes that are associated with the development of a particular disease or condition, or its underlying phenotype, and thus indicate a subject who has or is susceptible to developing the disease or condition. Furthermore, the genotypes disclosed herein are associated with increased expression or activity of TNFSF15 (TL1A). Thus, the genotypes indicate that the subject will have a positive therapeutic response to an inhibitor of TL1A activity or expression. Table 1 provides exemplary polymorphisms that are associated with, and thus indicate, a positive therapeutic response to an inhibitor of TNFSF15 (TL1A) expression or activity. The term "positive therapeutic response" refers to a reduction or elimination of at least one symptom of a disease or condition after the introduction of a treatment (e.g., an anti-TL1A antibody).
[0040] [Table 1]
[0041] The present disclosure provides a model including three polymorphisms (e.g., a "3-SNP model") that, when detected in a sample obtained from a subject, indicates a positive therapeutic response in the subject to treatment, e.g., with an inhibitor of TL1A activity or expression. Non-limiting examples of models described herein include Model A (rs6478109, rs7278257, and rs1892231); Model B (rs6478109, rs2070557, and rs9806914); Model C (rs6478109, rs7935393, and rs1892231); Model D (rs6478109, rs7935393, and rs9806914); Model E (rs6478109, rs9806914, and rs16901748); Model F (rs6478109, rs16901748, and rs2297437); Model G (rs6478109, rs1892231, and rs16901748); Model H (rs6478109, rs2070557, and rs7935393); Model I (rs6478109, rs7278257, and rs7935393); Model J (rs6478109, rs9806914, and rs1892231); and Model K (rs6478109, rs7278257, and rs16901748).
[0042] Treatment method Disclosed herein are methods of treating a disease or condition, or treating symptoms of a disease or condition, in a subject, the methods comprising administering to the subject a therapeutically effective amount of one or more therapeutic agents. In some embodiments, the one or more therapeutic agents are administered alone to the subject (e.g., standalone therapy). In some embodiments, the one or more therapeutic agents are administered in combination with additional agents. In some embodiments, the therapeutic agent is a first-line treatment for the disease or condition. In some embodiments, the therapeutic agent is a second-line, third-line, or fourth-line treatment for the disease or condition. In some embodiments, the therapeutic agent comprises an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression.
[0043] Various embodiments provide methods of treating inflammatory bowel disease (IBD), the methods comprising administering to a subject in need thereof an anti-TL1A antibody described herein. In some embodiments, the subject comprises one or more at-risk genotypes. In some embodiments, the IBD is a severe form of IBD.
[0044] In various embodiments, provided herein are methods of treating inflammatory bowel disease (IBD) in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment that specifically binds to TL1A. In some embodiments, the anti-TL1A antibody comprises antibody A. In some embodiments, the anti-TL1A antibody comprises antibody B. In some embodiments, the anti-TL1A antibody comprises antibody C. In some embodiments, the anti-TL1A antibody comprises antibody D. In some embodiments, the anti-TL1A antibody comprises antibody E. In some embodiments, the anti-TL1A antibody comprises antibody F. In some embodiments, the anti-TL1A antibody comprises antibody G. In some embodiments, the anti-TL1A antibody comprises antibody I. In some embodiments, the anti-TL1A antibody comprises antibody H. In some embodiments, the anti-TL1A antibody comprises antibody A2. In some embodiments, the anti-TL1A antibody comprises antibody B2. In some embodiments, the anti-TL1A antibody comprises antibody C2. In some embodiments, the anti-TL1A antibody comprises antibody D2. In some embodiments, the anti-TL1A antibody comprises antibody E2. In some embodiments, the anti-TL1A antibody comprises antibody F2. In some embodiments, the anti-TL1A antibody comprises antibody G2. In some embodiments, the anti-TL1A antibody comprises antibody I2. In some embodiments, the anti-TL1A antibody comprises antibody H2. In certain embodiments, the anti-TL1A antibody comprises any one of the antibodies in Table 10. In some embodiments, the anti-TL1A antibody comprises antibody A217. In some embodiments, the anti-TL1A antibody comprises antibody A220. In some embodiments, the anti-TL1A antibody comprises antibody A223. In some embodiments, the anti-TL1A antibody comprises antibody A219. In some embodiments, the anti-TL1A antibody comprises antibody A221. In some embodiments, the anti-TL1A antibody comprises antibody A200. In some embodiments, the anti-TL1A antibody comprises antibody A213. In some embodiments, the anti-TL1A antibody comprises antibody A212. In some embodiments, the anti-TL1A antibody comprises antibody A107. In some embodiments, the anti-TL1A antibody comprises antibody A205. In some embodiments, the anti-TL1A antibody comprises antibody A211. In some embodiments, the anti-TL1A antibody comprises antibody A199. In some embodiments, the anti-TL1A antibody comprises antibody A15.In some embodiments, the anti-TL1A antibody comprises antibody A30. In some embodiments, the anti-TL1A antibody comprises antibody A100. In some embodiments, the anti-TL1A antibody comprises antibody A181. In some embodiments, the anti-TL1A antibody comprises antibody A129. In some embodiments, the anti-TL1A antibody comprises antibody A214. In some embodiments, the anti-TL1A antibody comprises antibody A216. In some embodiments, the anti-TL1A antibody comprises antibody A122. In some embodiments, the anti-TL1A antibody comprises antibody A222. In some embodiments, the anti-TL1A antibody comprises antibody A188. In some embodiments, the anti-TL1A antibody comprises antibody A203. In some embodiments, the anti-TL1A antibody comprises antibody A147. In some embodiments, the anti-TL1A antibody comprises antibody A127. In some embodiments, the anti-TL1A antibody comprises antibody A126. In some embodiments, the anti-TL1A antibody comprises antibody A160. In some embodiments, the anti-TL1A antibody comprises antibody A157. In some embodiments, the anti-TL1A antibody comprises antibody A159. In some embodiments, the anti-TL1A antibody comprises antibody A218. In some embodiments, the anti-TL1A antibody comprises antibody A158. In some embodiments, the anti-TL1A antibody comprises antibody A125. In some embodiments, the anti-TL1A antibody comprises antibody A103. In some embodiments, the anti-TL1A antibody comprises antibody A64. In some embodiments, the anti-TL1A antibody comprises antibody A67. In some embodiments, the anti-TL1A antibody comprises antibody A138. In some embodiments, the anti-TL1A antibody comprises antibody A68. In some embodiments, the anti-TL1A antibody comprises antibody A94. In some embodiments, the anti-TL1A antibody comprises antibody A110. In some embodiments, the anti-TL1A antibody comprises antibody A197. In some embodiments, the anti-TL1A antibody comprises antibody A112. In some embodiments, the anti-TL1A antibody comprises antibody A169. In some embodiments, the anti-TL1A antibody comprises antibody A173. In some embodiments, the anti-TL1A antibody comprises antibody A179. In some embodiments, the anti-TL1A antibody comprises antibody A148. In some embodiments, the anti-TL1A antibody comprises antibody A115. In some embodiments, the anti-TL1A antibody comprises antibody A149.In some embodiments, the anti-TL1A antibody comprises antibody A134. In some embodiments, the anti-TL1A antibody comprises antibody A113. In some embodiments, the anti-TL1A antibody comprises antibody A151. In some embodiments, the anti-TL1A antibody comprises antibody A96. In some embodiments, the anti-TL1A antibody comprises antibody A132. In some embodiments, the anti-TL1A antibody comprises antibody A196. In some embodiments, the anti-TL1A antibody comprises antibody A172. In some embodiments, the anti-TL1A antibody comprises antibody A75. In some embodiments, the anti-TL1A antibody comprises antibody A174. In some embodiments, the anti-TL1A antibody comprises antibody A109. In some embodiments, the anti-TL1A antibody comprises antibody A198. In some embodiments, the anti-TL1A antibody comprises antibody A170. In certain embodiments, the anti-TL1A antibody comprises any one of the antibodies in Tables 20-21. In some embodiments, the anti-TL1A antibody comprises antibody clone 34. In some embodiments, the anti-TL1A antibody comprises antibody 5C3D11. In some embodiments, the anti-TL1A antibody comprises antibody 9E12E5. In some embodiments, the anti-TL1A antibody comprises antibody AS12824. In some embodiments, the anti-TL1A antibody comprises antibody AS12823. In some embodiments, the anti-TL1A antibody comprises antibody AS12819. In some embodiments, the anti-TL1A antibody comprises antibody AS12816. In some embodiments, the anti-TL1A antibody comprises antibody AS12825. In some embodiments, the anti-TL1A antibody comprises antibody 12835. In some embodiments, the anti-TL1A antibody comprises antibody 18-7 S93E. In some embodiments, the anti-TL1A antibody comprises antibody 18-7. In some embodiments, the anti-TL1A antibody comprises antibody 18-7 S92D. In some embodiments, the anti-TL1A antibody comprises antibody 18-7 S92H. In some embodiments, the anti-TL1A antibody comprises antibody 18-7 S92N. In some embodiments, the anti-TL1A antibody comprises antibody 18-7 S92Q. In some embodiments, the anti-TL1A antibody comprises antibody 18-7 CDRv. In some embodiments, the anti-TL1A antibody comprises antibody 21-3. In some embodiments, the anti-TL1A antibody comprises antibody 21-3 V102K.In some embodiments, the anti-TL1A antibody comprises antibody 21-3 V102M. In some embodiments, the anti-TL1A antibody comprises antibody 21-3 V102Q. In some embodiments, the anti-TL1A antibody comprises antibody 21-3 V102W. In some embodiments, the anti-TL1A antibody comprises antibody 21-3 CDRv. In some embodiments, the anti-TL1A antibody comprises antibody 21-3 CDRv. In some embodiments, the anti-TL1A antibody comprises antibody clone 2. In some embodiments, the anti-TL1A antibody comprises antibody clone 52. In some embodiments, the anti-TL1A antibody comprises antibody clone 46. In some embodiments, the anti-TL1A antibody comprises antibody clone 47. In some embodiments, the anti-TL1A antibody comprises antibody clone 14. In some embodiments, the anti-TL1A antibody comprises antibody clone 16L. In some embodiments, the anti-TL1A antibody comprises antibody clone 17L. In some embodiments, the anti-TL1A antibody comprises antibody clone 17L-1. In some embodiments, the anti-TL1A antibody comprises antibody clone 23. In some embodiments, the anti-TL1A antibody comprises antibody clone 53. In some embodiments, the anti-TL1A antibody comprises antibody clone E1. In some embodiments, the anti-TL1A antibody comprises antibody clone 3-17L VA. In some embodiments, the anti-TL1A antibody comprises antibody clone 3-17L. In some embodiments, the anti-TL1A antibody comprises antibody clone L8mod. In some embodiments, the anti-TL1A antibody comprises antibody clone XV. In some embodiments, the anti-TL1A antibody comprises antibody clone X. In some embodiments, the anti-TL1A antibody comprises antibody clone XL3-6. In some embodiments, the anti-TL1A antibody comprises antibody clone XL3-10. In some embodiments, the anti-TL1A antibody comprises antibody clone XL3-15. In some embodiments, the anti-TL1A antibody comprises antibody clone L3-13. In some embodiments, the anti-TL1A antibody comprises antibody clone H3-1. In some embodiments, the anti-TL1A antibody comprises antibody clone H2-2. In some embodiments, the anti-TL1A antibody comprises antibody clone H2-5. In some embodiments, the anti-TL1A antibody comprises antibody M1. In some embodiments, the anti-TL1A antibody comprises antibody M2.In some embodiments, the anti-TL1A antibody comprises antibody M3. In some embodiments, the anti-TL1A antibody comprises antibody M4. In some embodiments, the anti-TL1A antibody comprises antibody M5. In some embodiments, the anti-TL1A antibody comprises antibody M6. In some embodiments, the anti-TL1A antibody comprises antibody M7. In some embodiments, the anti-TL1A antibody comprises antibody M8. In some embodiments, the anti-TL1A antibody comprises antibody M9. In some embodiments, the anti-TL1A antibody comprises antibody M10. In some embodiments, the anti-TL1A antibody comprises antibody M11. In some embodiments, the anti-TL1A antibody comprises antibody M12.
[0045] The methods disclosed herein provide methods of treating inflammatory bowel disease (IBD) in a subject by administering to the subject an anti-TL1A antibody described herein. In various embodiments, the IBD is Crohn's disease (CD) or ulcerative colitis (UC). In some embodiments, the IBD is a severe form of IBD. In some embodiments, the IBD is a moderate to severe form of IBD. In some embodiments, the IBD is a moderate form of IBD. In various other embodiments, the subject is determined to have increased TL1A expression. In some embodiments, administering a therapeutically effective amount of the anti-TL1A antibody reduces TL1A in the treated subject.
[0046] Detection Method Disclosed herein are methods for detecting genotypes in a sample from a subject, the methods comprising analyzing genetic material in the sample to detect at least one of the presence, absence, and amount of a nucleic acid sequence comprising the subject's genotype, and administering an anti-TL1A antibody or antigen-binding fragment disclosed herein. In some embodiments, the sample is analyzed to determine the presence, absence, or amount of at least three polymorphisms. In some embodiments, the sample is analyzed to determine the presence, absence, or amount of at least four polymorphisms. In some embodiments, the sample is analyzed to determine the presence, absence, or amount of at least five polymorphisms. In some embodiments, the sample is analyzed to determine the presence, absence, or amount of at least six polymorphisms. In some embodiments, the sample is analyzed to determine the presence, absence, or amount of at least seven polymorphisms. In some embodiments, the sample is analyzed to determine the presence, absence, or amount of at least eight polymorphisms. In some embodiments, at least three genotypes are detected using the methods described herein. In some embodiments, at least eight genotypes are detected using the methods described herein.
[0047] In some cases, the nucleic acid sequence comprises DNA. In some cases, the nucleic acid sequence comprises a denatured DNA molecule or a fragment thereof. In some cases, the nucleic acid sequence comprises DNA selected from genomic DNA, viral DNA, mitochondrial DNA, plasmid DNA, amplified DNA, circular DNA, circulating DNA, cell-free DNA, or exosomal DNA. In some cases, the DNA is single-stranded DNA (ssDNA), double-stranded DNA, denatured double-stranded DNA, synthetic DNA, and combinations thereof. The circular DNA may be cleaved or fragmented. In some cases, the nucleic acid sequence comprises RNA. In some cases, the nucleic acid sequence comprises fragmented RNA. In some cases, the nucleic acid sequence comprises partially degraded RNA. In some cases, the nucleic acid sequence comprises microRNA or a portion thereof. In some examples, the nucleic acid sequence comprises an RNA molecule selected from microRNA (miRNA), pre-miRNA, pri-miRNA, mRNA, pre-mRNA, viral RNA, viroid RNA, virusoid RNA, circular RNA (circRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), pre-tRNA, long non-coding RNA (lncRNA), small nuclear RNA (snRNA), circular RNA, cell-free RNA, exosomal RNA, vector-expressed RNA, RNA transcript, synthetic RNA, or a fragmented RNA molecule (RNA fragment).
[0048] Nucleic acid-based detection techniques that may be useful in the methods herein include quantitative polymerase chain reaction (qPCR), gel electrophoresis, immunochemical methods, in situ hybridization, such as fluorescent in situ hybridization (FISH), cytochemical methods, and next-generation sequencing. In some embodiments, the method includes TaqMan™ qPCR, which involves a nucleic acid amplification reaction with a specific primer pair and hybridization of the amplified nucleic acid with a hydrolytic probe specific to the target nucleic acid.
[0049] In some examples, the method includes a hybridization assay and / or an amplification assay, including, but not limited to, Southern or Northern analysis, polymerase chain reaction analysis, and probe arrays. Non-limiting examples of amplification reactions include, but are not limited to, qPCR, self-sustained sequence replication, transcription amplification systems, Q-beta replicase, rolling circle replication, or any other nucleic acid amplification method known in the art. As discussed herein, reference to qPCR includes the use of TaqMan™ technology. Additional exemplary hybridization assays include the use of nucleic acid probes conjugated or otherwise immobilized on beads, multiwell plates, or other substrates, where the nucleic acid probes are configured to hybridize with the target nucleic acid sequences of the genotypes provided herein. A non-limiting example is the method described in Anal Chem. 2013 Feb 5; 85(3):1932-9.
[0050] In some embodiments, detecting the presence or absence of genotype comprises sequencing the genetic material from the subject.Sequencing can be carried out by any suitable sequencing technology, including but not limited to single-molecule real-time (SMRT) sequencing, polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, sequencing by binding (e.g., transient binding) or sequencing by synthesis. Sequencing methods also include next-generation sequencing, and include the latest sequencing technology such as Illumina sequencing (for example, Solexa), Roche 454 sequencing, Ion torrent sequencing, transient binding sequencing and SOLiD sequencing.In some examples, next-generation sequencing includes high-throughput sequencing method.Additional sequencing methods available to those skilled in the art can also be adopted.
[0051] In some examples, the number of nucleotides sequenced is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500, 2000, 4000, 6000, 8000, 10000, 20000, 50000, 100000 nucleotides, or greater than 100000 nucleotides. In some examples, the number of nucleotides to be sequenced is about 1 to about 100,000 nucleotides, about 1 to about 10,000 nucleotides, about 1 to about 1,000 nucleotides, about 1 to about 500 nucleotides, about 1 to about 300 nucleotides, about 1 to about 200 nucleotides, about 1 to about 100 nucleotides, about 5 to about 100,000 nucleotides, about 5 to about 10,000 nucleotides, about 5 to about 1,000 nucleotides, about 5 to about 500 nucleotides, about 5 to about 300 nucleotides, about 5 to about 200 nucleotides, about 5 to about 100 nucleotides, about 10 to about 100,000 nucleotides, about 10 to about 10,000 nucleotides, about 10 to about 1,000 nucleotides, about 10 to about 500 nucleotides, about 10 to about 300 nucleotides, or about 10 to about 200 nucleotides. nucleotides, about 10 to about 100 nucleotides, about 20 to about 100,000 nucleotides, about 20 to about 10,000 nucleotides, about 20 to about 1,000 nucleotides, about 20 to about 500 nucleotides, about 20 to about 300 nucleotides, about 20 to about 200 nucleotides, about 20 to about 100 nucleotides, about 30 to about 100,000 nucleotides, about 30 to about 10,000 nucleotides, about 30 to about 1,000 nucleotides, about 30 to about 500 nucleotides, about 30 to about 300 nucleotides, about 30 to about 200 nucleotides, about 30 to about 100 nucleotides, about 50 to about 100,000 nucleotides, about 50 to about 10,000 nucleotides, about 50 to about 1,000 nucleotides, about 50 to about 500 nucleotides, about 50 to about 300 nucleotides, about 50 to about 200 nucleotides, or in the range of about 50 to about 100 nucleotides.
[0052] Exemplary probes include a nucleic acid sequence of at least 10 contiguous nucleic acids as provided in any one of SEQ ID NOs: 2001-2048 or 2057-2059, comprising nucleobases designated by non-nucleobase characters (e.g., R, N, S) or their reverse complements. In some examples, a probe may be used to detect a polymorphism provided in Table 1, wherein the probe comprises a nucleic acid sequence of at least 10 contiguous nucleic acids as provided in the corresponding SEQ ID NO or its reverse complement, the 10 contiguous nucleic acids comprising a "risk allele," the risk allele being provided in Table 1 at a nucleic acid position designated by the non-nucleobase character or its reverse complement. In some embodiments, the probe comprises at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 2001-2048 or 2057-2059, or their reverse complements. In some examples, forward and reverse primers are used to amplify a target nucleic acid sequence. The forward and reverse primers may contain nucleic acid sequences flanking the risk alleles provided in Table 1, corresponding to the nucleic acid sequences provided in any one of SEQ ID NOS: 2001-2048, or 2057-2059, or their reverse complements.
[0053] Examples of molecules utilized as probes include, but are not limited to, RNA and DNA. In some embodiments, with respect to nucleic acids, the term "probe" refers to any molecule capable of selectively binding to a specifically intended target nucleic acid sequence. In some examples, probes are specifically designed to be labeled with, for example, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, or other labels or tags known in the art. In some examples, the fluorescent label comprises a fluorophore. In some examples, the fluorophore is an aromatic or heteroaromatic compound. In some examples, the fluorophore is pyrene, anthracene, naphthalene, acridine, stilbene, benzoxazole, indole, benzoindole, oxazole, thiazole, benzothiazole, canine, carbocyanine, salicylate, anthranilate, xanthene dye, or coumarin. Exemplary xanthene dyes include, for example, fluorescein dyes and rhodamine dyes. Fluorescein and rhodamine dyes include, but are not limited to, 6-carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), tetrachlorofluorescein (TET), 6-carboxyrhodamine (R6G), N,N,N;N'-tetramethyl-6-carboxyrhodamine (TAMRA), and 6-carboxy-X-rhodamine (ROX). Suitable fluorescent probes also include naphthylamine dyes with an amino group at the alpha or beta position. For example, naphthylamino compounds include 1-dimethylaminonaphthyl-5-sulfonate, 1-anilino-8-naphthalenesulfonate, and 2-p-toluidinyl-6-naphthalenesulfonate, 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS).Exemplary coumarins include, for example, 3-phenyl-7-isocyanatocoumarin; acridines, such as 9-isothiocyanatoacridine and acridine orange; N-(p-(2-benzoxazolyl)phenyl)maleimide; cyanines, such as indodicarbocyanine 3 (Cy3), indodicarbocyanine 5 (Cy5), indodicarbocyanine 5.5 (Cy5.5), 3-(-carboxy-pentyl)-3'-ethyl-5,5'-dimethyloxacarbocyanine (CyA); 1H, 5H, 11H, 15H-xantheno[2,3, 4-ij: 5,6, 7-i'j']diquinolizin-18-ium, 9-[2 (or 4)-[[[6-[2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4 (or 2)-sulfophenyl]-2,3, 6,7, 12,13, 16,17-octahydro-inner salt (TR or Texas Red); or BODIPY™ dye. In some examples, the probe includes FAM as the dye label.
[0054] In some examples, the primers and / or probes described herein for detecting target nucleic acids are used in an amplification reaction. In some examples, the amplification reaction is qPCR. An exemplary qPCR method is a TaqMan™ assay. Non-limiting examples of primer pairs useful for detecting one or more polymorphisms described herein are provided in Table 2 below.
[0055] [Table 2]
[0056] "Wt_Probe_Hex" and "Mut_Probe_FAM" refer to "wild-type_probe_HEX reporter dye-tagged" and "Mut_probe_FAM reporter dye-tagged," respectively. "+" represents an LNA base (locked nucleotide), which is an analog modified at 2'-O, 4'-C to form a bridge. This bridge restricts base pairing and allows space between probes to adjust Tm as needed. Thus, +A, +T, +C, or +G represents the addition of an A, T, G, or C base onto the modified backbone.
[0057] In some examples, qPCR involves using an intercalating dye. Examples of intercalating dyes include SYBR green I, SYBR green II, SYBR gold, ethidium bromide, methylene blue, pyronin Y, DAPI, acrylidine orange, Blue View, or phycoerythrin. In some examples, the intercalating dye is SYBR.
[0058] In some examples, the number of amplification cycles for detecting a target nucleic acid in an amplification assay is about 5 to about 30 cycles. In some examples, the number of amplification cycles for detecting a target nucleic acid is at least about 5 cycles. In some examples, the number of amplification cycles for detecting a target nucleic acid is at most about 30 cycles. In some examples, the number of amplification cycles for detecting a target nucleic acid is about 5 to about 10, about 5 to about 15, about 5 to about 20, about 5 to about 25, about 5 to about 30, about 10 to about 15, about 10 to about 20, about 10 to about 25, about 10 to about 30, about 15 to about 20, about 15 to about 25, about 15 to about 30, about 20 to about 25, about 20 to about 30, or about 25 to about 30 cycles.
[0059] In one aspect, the methods provided herein for determining the presence, absence, and / or quantity of nucleic acid sequences from a particular genotype include an amplification reaction, such as qPCR. In an exemplary method, genetic material is obtained from a subject's sample, such as a blood or serum sample. In certain embodiments in which nucleic acids are extracted, the nucleic acids are extracted using any technique that does not interfere with subsequent analysis. In certain embodiments, the technique uses alcohol precipitation using ethanol, methanol, or isopropyl alcohol. In certain embodiments, the technique uses phenol, chloroform, or any combination thereof. In certain embodiments, the technique uses cesium chloride. In certain embodiments, the technique uses sodium, potassium, or ammonium acetate, or any other salt commonly used to precipitate DNA. In certain embodiments, the technique utilizes a column- or resin-based nucleic acid purification scheme, such as those commonly available commercially. One non-limiting example is the GenElute Bacterial Genomic DNA Kit available from Sigma-Aldrich. In certain embodiments, after extraction, the nucleic acid is stored in water, Tris buffer, or Tris-EDTA buffer prior to subsequent analysis. In exemplary embodiments, the nucleic acid material is extracted in water. In some instances, extraction does not include nucleic acid purification.
[0060] In an exemplary qPCR assay, a nucleic acid sample is mixed with primers and probes, and a polymerase, where the primers and probes are specific for a target nucleic acid that may or may not be present in the sample. The amplification reaction is carried out using a thermal cycler. The thermal cycler heats and cools the sample to amplify the nucleic acid, and then illuminates the sample with a specific wavelength to excite the fluorophore on the probe and detect the emitted fluorescence. For the TaqMan™ method, the probe may be a hydrolyzable probe containing a fluorophore and a quencher. This probe is hydrolyzed by DNA polymerase when hybridized to the target nucleic acid. In some examples, the presence of the target nucleic acid is determined when the number of amplification cycles that reach a threshold is less than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or 20 cycles.
[0061] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2001 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:2001. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2001 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:2001. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:2001 is sufficient to detect a polymorphism at rs11897732.
[0062] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2002 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:2002. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2002 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:2002. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:2002 is sufficient to detect a polymorphism at rs6740739.
[0063] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2003 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2003. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2003 and comprises a "G" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 2003. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 2003 is sufficient to detect a polymorphism at rs17796285.
[0064] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2004 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2004. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2004 and comprises a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 2004. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 2004 is sufficient to detect a polymorphism at rs7935393.
[0065] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2005 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2005. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2005 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 2005. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 2005 is sufficient to detect a polymorphism at rs12934476.
[0066] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2006 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2006. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2006 and comprises an "A" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 2006. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 2006 is sufficient to detect a polymorphism at rs12457255.
[0067] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2007 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:2007. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2007 and comprises an "A" allele or a "T" allele at nucleic acid position 501 in SEQ ID NO:2007. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "T" allele at nucleic acid position 501 in SEQ ID NO:2007 is sufficient to detect a polymorphism at rs2070557.
[0068] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2008 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2008. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2008 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 2008. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 2008 is sufficient to detect a polymorphism at rs4246905.
[0069] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2009 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2009. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 2009 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 2009. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 2009 is sufficient to detect a polymorphism at rs10974900.
[0070] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2010 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:2010. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:2010 and comprises a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:2010. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:2010 is sufficient to detect a polymorphism at rs12434976.
[0071] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20011 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20011. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20011 and comprises an "A" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO:20011. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO:20011 is sufficient to detect a polymorphism at rs16901748.
[0072] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20012 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20012. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20012 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20012. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20012 is sufficient to detect a polymorphism at rs2815844.
[0073] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20013 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20013. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20013 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20013. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:2013 is sufficient to detect a polymorphism at rs889702.
[0074] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20014 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20014. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20014 and comprises a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20014. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20014 is sufficient to detect a polymorphism at rs2409750.
[0075] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20015 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20015. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20015 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:20015. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:2015 is sufficient to detect a polymorphism at rs1541020.
[0076] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20016 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20016. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20016 and comprises a "T" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:2016. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "T" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20016 is sufficient to detect a polymorphism at rs4942248.
[0077] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20017 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20017. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20017 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20017. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20017 is sufficient to detect a polymorphism at rs12934476.
[0078] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20018 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20018. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20018 and comprises an "A" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 20018. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 20018 is sufficient to detect a polymorphism at rs12457255.
[0079] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20019 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20019. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20019 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20019. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20019 is sufficient to detect a polymorphism at rs2297437.
[0080] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20020 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20020. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20020 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20020. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20020 is sufficient to detect a polymorphism at rs41309367.
[0081] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20021 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20021. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20021 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:2021. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:20021 is sufficient to detect a polymorphism at rs10733509.
[0082] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20022 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20022. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20022 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20022. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20022 is sufficient to detect a polymorphism at rs10750376.
[0083] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20023 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20023. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20023 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20023. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20023 is sufficient to detect a polymorphism at rs10932456.
[0084] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20024 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20024. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20024 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20024. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20024 is sufficient to detect a polymorphism at rs1326860.
[0085] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20025, and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20025. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20025 is sufficient to detect a polymorphism at rs1528663.
[0086] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20026 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20026. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20026 and comprises a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20026. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20026 is sufficient to detect a polymorphism at rs1892231.
[0087] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20027 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20027. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20027 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20027. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20027 is sufficient to detect a polymorphism at rs951279.
[0088] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20028 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20028. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20028 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20028. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20028 is sufficient to detect a polymorphism at rs9806914.
[0089] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20029 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20029. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20029 and comprises a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20029. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20029 is sufficient to detect a polymorphism at rs7935393.
[0090] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20030 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20030. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20030 and comprises a "G" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 20030. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 20030 is sufficient to detect a polymorphism at rs1690492.
[0091] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20031 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20031. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20031 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20031. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO:20031 is sufficient to detect a polymorphism at rs420726.
[0092] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20032 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20032. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20032 and comprises a "T" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20032. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "T" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20032 is sufficient to detect a polymorphism at rs7759385.
[0093] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20033 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20033. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20033 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20033. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20033 is sufficient to detect a polymorphism at rs10974900.
[0094] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20034 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20034. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20034 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20034. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20034 is sufficient to detect a polymorphism at rs1326860.
[0095] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20035 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 2035. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20035 and comprises a "C" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20035. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20035 is sufficient to detect a polymorphism at rs2548147.
[0096] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20036 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20036. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20036 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20036. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20036 is sufficient to detect a polymorphism at rs2815844.
[0097] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20037 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20037. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20037 and comprises a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20037. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "G" allele or an "A" allele at nucleic acid position 501 in SEQ ID NO: 20037 is sufficient to detect a polymorphism at rs889702.
[0098] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20038 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20038. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20038 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20038. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20038 is sufficient to detect a polymorphism at rs9806914.
[0099] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20039 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20039. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20039 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20039. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20039 is sufficient to detect a polymorphism at rs6478109.
[0100] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20040 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20040. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20040 and comprises a "C" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20040. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "C" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 2040 is sufficient to detect a polymorphism at rs7278257.
[0101] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20041 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO:20041. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO:20041 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:20041. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO:20041 is sufficient to detect a polymorphism at rs11221332.
[0102] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20057 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20057. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20057 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20057. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20057 is sufficient to detect a polymorphism at rs56124762.
[0103] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20058 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20058. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20058 and comprises an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20058. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising an "A" allele or a "G" allele at nucleic acid position 501 in SEQ ID NO: 20058 is sufficient to detect a polymorphism at rs2070558.
[0104] In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20059 and comprises a non-reference allele at nucleic acid position 501 in SEQ ID NO: 20059. In some embodiments, the target nucleic acid is at least 10 contiguous nucleic acid molecules of SEQ ID NO: 20059 and comprises a "T" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 20059. In some embodiments, detection of at least 10 contiguous nucleic acid molecules comprising a "T" allele or a "C" allele at nucleic acid position 501 in SEQ ID NO: 20059 is sufficient to detect a polymorphism at rs2070561.
[0105] In some embodiments, one target nucleic acid (e.g., polymorphism) is detected by the methods disclosed herein. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 target nucleic acids are detected. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 target nucleic acids are detected in a single multiplex assay. In some embodiments, when four target nucleic acids are detected in a sample from a subject, four unique 3-polymorphism combinations are measured. In a non-limiting example, a sample (e.g., blood or plasma) obtained from a subject is contacted with four primer pairs, each adapted to individually amplify rs6487109, rs56124762, rs1892231, and rs16901748, respectively. Positive, negative or indeterminate TNFSF15 profile can depend at least in part on which combination of 3-polymorphisms is detected in sample and / or whether the genotype is heterozygous or homozygous for the polymorphism.In this example, analyzing 4 polymorphisms means that a total of 4 unique 3-polymorphisms can be detected in patient sample, which are: rs6478109, rs56124762, rs1892231; rs6478109, rs56124762, rs16901748; rs6478109, rs1892231, rs16901748; and rs56124762, rs1892231, rs16901748.Each detected polymorphism can be heterozygous or homozygous.
[0106] In some aspects, disclosed herein are sample preparation methods, including (a) extracting a plurality of nucleic acids from a sample obtained from a subject as disclosed herein, and (b) enriching a target nucleic acid from the plurality of nucleic acids containing one or more polymorphisms disclosed herein, wherein the enrichment is carried out by (i) contacting the sample with a liquid reaction formulation containing synthetic oligonucleotide molecules, (ii) hybridizing the synthetic oligonucleotide molecules with the target nucleic acid molecule, and (iii) amplifying the target nucleic acid molecule to enrich the target nucleic acid molecule in the liquid reaction formulation. In some embodiments, the method further includes detecting the target nucleic acid molecule enriched in (b). In some embodiments, the target nucleic acid comprises a TNFSF15 locus. In some embodiments, the one or more polymorphisms include a polymorphism provided in Table 1. In some embodiments, the one or more polymorphisms include a combination of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more of the polymorphisms provided in Table 1. In some embodiments, the synthetic oligonucleotide comprises a primer sequence. In some embodiments, the synthetic oligonucleotide comprises a detector probe.
[0107] To practice the methods and systems provided herein, genetic material may be extracted from a sample obtained from a subject, such as a blood or serum sample. In certain embodiments in which nucleic acids are extracted, the nucleic acids are extracted using any technique that does not interfere with subsequent analysis. In certain embodiments, the technique uses alcohol precipitation using ethanol, methanol, or isopropyl alcohol. In certain embodiments, the technique uses phenol, chloroform, or any combination thereof. In certain embodiments, the technique uses cesium chloride. In certain embodiments, the technique uses sodium, potassium, or ammonium acetate, or any other salt commonly used to precipitate DNA. In certain embodiments, the technique utilizes a column- or resin-based nucleic acid purification scheme, such as those commonly available commercially. One non-limiting example is the GenElute Bacterial Genomic DNA Kit available from Sigma-Aldrich. In certain embodiments, after extraction, the nucleic acids are stored in water, Tris buffer, or Tris-EDTA buffer prior to subsequent analysis. In exemplary embodiments, the nucleic acid material is extracted in water. In some examples, the extraction does not include nucleic acid purification. In certain embodiments, RNA may be extracted from cells using RNA extraction methods including, for example, acid phenol / guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA preparation kit (Qiagen), or PAXgene (PreAnalytix, Switzerland).
[0108] In some embodiments, methods for detecting the presence, absence, or level of a target protein (e.g., a biomarker) in a sample obtained from a subject include detecting protein activity or expression. In some embodiments, the target protein is TL1A or a binding partner of TL1A, such as, for example, Death Domain Receptor 3 (DcR3). The target protein may be detected using an antibody-based assay, which utilizes an antibody specific to the target protein. In some embodiments, the antibody-based detection method utilizes an antibody that binds to any region of the target protein. An exemplary analytical method includes performing an enzyme-linked immunosorbent assay (ELISA). The ELISA assay may be a sandwich ELISA or a direct ELISA. Another exemplary analytical method includes a single molecule array, e.g., Simoa. Other exemplary detection methods include immunohistochemistry and lateral flow assays. Additional examples of methods for detecting target proteins include, but are not limited to, gel electrophoresis, capillary electrophoresis, high-performance liquid chromatography (HPLC), thin-layer chromatography (TLC), hyperdiffusion chromatography, etc., or various immunological methods, such as, for example, hydrophobic or gel precipitation, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay (RIA), immunofluorescence assay, and Western blotting. In some embodiments, antibodies or antibody fragments are used in methods such as Western blotting or immunofluorescence to detect expressed proteins. Antibodies or proteins may be immobilized on solid supports for Western blotting and immunofluorescence. Suitable solid supports or carriers include any support capable of binding antigens or antibodies. Exemplary supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural and modified cellulose, polyacrylamide, gabbro, and magnetite.
[0109] In some examples, the target protein may be detected by detecting binding between the target protein and a binding partner of the target protein. Non-limiting examples of binding partners of TL1A include DcR3 and tumor necrosis factor receptor superfamily member 25 (TNR25). Examples of methods for analyzing protein-protein binding include performing assays in vivo, in vitro, or ex vivo. In some examples, the analysis methods include, for example, co-immunoprecipitation (co-IP), pull-down, cross-linking protein interaction analysis, label-transfer protein interaction analysis, or Far-Western blot analysis, FRET-based analysis, including FRET-FLIM, yeast two-hybrid assay, BiFC, or split luciferase assay.
[0110] Disclosed herein are methods for detecting the presence or level of one or more serum markers in a sample obtained from a subject. In some embodiments, the one or more serological markers include anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic antibodies (ANCA), antibodies against Escherichia coli outer membrane porin protein C (anti-OmpC), anti-chitin antibodies, pANCA antibodies, anti-I2 antibodies, and anti-Cbir1 flagellin antibodies. In some embodiments, the antibodies include immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin E (IgE), or immunoglobulin M (IgM), immunoglobulin D (IgD), or a combination thereof. Any suitable method for detecting the target proteins or biomarkers disclosed herein may be used to detect the presence, absence, or level of the serological markers. In some embodiments, the presence or level of one or more serological markers is detected using enzyme-linked immunosorbent assay (ELISA), single molecule array (Simoa), immunohistochemistry, internal transcribed spacer (ITS) sequencing, or any combination thereof. In some embodiments, the ELISA is a fixed leukocyte ELISA. In some embodiments, the ELISA is a fixed neutrophil ELISA. Fixed leukocyte or neutrophil ELISAs may be useful for detecting specific serological markers, such as those described in Saxon et al. A unique subset of antineutrophil cytoplasmic antibodies has been associated with inflammatory bowel disease. J. Allergy Clin. Immuno. 86:2; 202-210 (August 1990). In some embodiments, ELISA units (EU) are used to measure the positivity (e.g., seropositivity) of the presence or level of a serological marker. This positivity reflects a percentage of a standard or reference value. In some embodiments, the standard comprises pooled serum obtained from a well-characterized patient population (a population diagnosed with or suspected of having the same disease or condition as the subject).In some embodiments, the control or reference value comprises 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 EU. In some examples, the quartile sum score is calculated using the method reported in, for example, Landers CJ, Cohavy O, Misra R. et al., Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology (2002) 123:689-699. therapeutic agent
[0111] antibody In one aspect, provided herein are antibodies and antigen-binding fragments. In some embodiments, an antibody includes an antigen-binding fragment, where an antigen-binding fragment refers to a portion of an antibody comprising the antigenic determining variable region of the antibody. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, single-chain antibodies, and multispecific antibodies formed from antibody fragments. In some embodiments, an antibody refers to an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing, through at least one antigen recognition site within the variable region of the immunoglobulin molecule. In some embodiments, antibodies include intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) variants, CDR-grafted antibodies, multispecific antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins containing antigenic determinants of an antibody, and any other modified immunoglobulin molecule containing an antigen recognition site, provided that the antibody exhibits the desired biological activity. Antibodies may be any of the five major immunoglobulin classes: IgA, IgD, IgE, IgG, and IgM, or their subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the identity of the heavy chain constant domains, designated alpha, delta, epsilon, gamma, and mu, respectively. Different classes of immunoglobulins have distinct and known subunit structures and three-dimensional configurations. Antibodies may be naked or conjugated to other molecules, such as toxins, radioisotopes, etc.
[0112] In some embodiments, a humanized antibody refers to a form of a non-human (e.g., murine) antibody having a particular immunoglobulin chain, chimeric immunoglobulin, or fragment thereof that contains minimal non-human (e.g., murine) sequences. In a non-limiting example, a humanized antibody contains less than about 40% non-human sequences in the variable region. In some examples, a humanized antibody contains less than about 20% non-human sequences in the full-length antibody sequence. In a further non-limiting example, a humanized antibody contains less than about 20% non-human sequences in the framework regions of each of the heavy and light chain variable regions. For example, a humanized antibody contains less than about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% non-human sequences in the framework regions of each of the heavy and light chain variable regions. In another example, a humanized antibody comprises less than about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 non-human sequence in the framework regions of each of the heavy and light chain variable regions. In some examples, humanized antibodies are human immunoglobulins in which residues from the complementarity-determining regions (CDRs) are replaced by residues from CDRs of a non-human species (e.g., mouse, rat, rabbit, hamster) having the desired specificity, affinity, and capacity. These humanized antibodies may contain one or more non-human species mutations, for example, the heavy chain may contain about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 non-human species mutations in the framework regions, and the light chain may contain about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 non-human species mutations in the framework regions. The humanized heavy chain variable domain may comprise an IGHV1-46*02 framework with less than about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations, or no amino acid mutations. The humanized light chain variable domain may comprise an IGKV3-20 framework with less than about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations, or no amino acid mutations.
[0113] In some embodiments, a chimeric antibody refers to an antibody in which the sequences of its immunoglobulin molecules are derived from two or more species. As a non-limiting example, the variable regions of both the light and heavy chains correspond to the variable regions of antibodies with the desired specificity, affinity, and capacity derived from one species of mammal (e.g., mouse, rat, rabbit, etc.), while the constant regions are homologous to antibody sequences derived from another species (usually human), thereby avoiding eliciting an immune response in that species.
[0114] In certain aspects, antibodies that specifically bind to TL1A are described herein (Entrez Gene: 9966; UniProtKB: O95150). In some embodiments, the antibody specifically binds to soluble TL1A. In some embodiments, the antibody specifically binds to membrane-bound TL1A. In some embodiments, an anti-TL1A antibody is provided having a heavy chain comprising the following four heavy chain framework regions (HCFRs) and three heavy chain complementarity-determining regions (HCDRs): HCFR1, HCDR1, HCFR2, HCDR2, HCFR3, HCDR3, and HCFR4; and a light chain comprising the following four light chain framework regions (LCFRs) and three light chain complementarity-determining regions (LCDRs): LCFR1, LCDR1, LCFR2, LCDR2, LCFR3, LCDR3, and LCFR4. The anti-TL1A antibody may comprise any of the regions provided herein, for example, as provided in Tables 15-21, the Examples, and the sequences. Exemplary Anti-TL1A CDRs
[0115] In certain embodiments, the anti-TL1A antibody comprises an HCDR1 set forth in any one of SEQ ID NOs: 1 or 601-722. In certain embodiments, the anti-TL1A antibody comprises an HCDR2 set forth in any one of SEQ ID NOs: 2-5 or 723-787. In certain embodiments, the anti-TL1A antibody comprises an HCDR3 set forth in any one of SEQ ID NOs: 6-9 or 788-842. In certain embodiments, the anti-TL1A antibody comprises an LCDR1 set forth in any one of SEQ ID NOs: 10 or 843-865. In certain embodiments, the anti-TL1A antibody comprises an LCDR2 set forth in any one of SEQ ID NOs: 11 or 866-885. In certain embodiments, the anti-TL1A antibody comprises an LCDR3 set forth in any one of SEQ ID NOs: 12-15 or 886-1101.
[0116] In one aspect, the present specification provides an anti-TL1A antibody having an HCDR1 comprising any one of SEQ ID NOs: 1 or 601 to 708, an HCDR2 comprising any one of SEQ ID NOs: 2 to 5 or 723 to 774, an HCDR3 comprising any one of SEQ ID NOs: 6 to 9 or 788 to 828, an LCDR1 comprising any one of SEQ ID NOs: 10 or 843 to 852, an LCDR2 comprising any one of SEQ ID NOs: 11 or 866 to 873, and an LCDR3 comprising any one of SEQ ID NOs: 12 to 15 or 886 to 1089.
[0117] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 709, an HCDR2 comprising SEQ ID NO: 775, an HCDR3 comprising SEQ ID NO: 829, an LCDR1 comprising SEQ ID NO: 853, an LCDR2 comprising SEQ ID NO: 874, and an LCDR3 comprising SEQ ID NO: 1090.
[0118] In one embodiment, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 710, an HCDR2 comprising SEQ ID NO: 776, an HCDR3 comprising SEQ ID NO: 830, an LCDR1 comprising SEQ ID NO: 854, an LCDR2 comprising SEQ ID NO: 875, and an LCDR3 comprising SEQ ID NO: 1091. In one embodiment, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 711 or 712, an HCDR2 comprising SEQ ID NO: 777 or 778, an HCDR3 comprising SEQ ID NO: 831 or 832, an LCDR1 comprising SEQ ID NO: 855, an LCDR2 comprising SEQ ID NO: 876, and an LCDR3 comprising SEQ ID NO: 1092.
[0119] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 713, an HCDR2 comprising SEQ ID NO: 779, an HCDR3 comprising SEQ ID NO: 833, an LCDR1 comprising SEQ ID NO: 856, an LCDR2 comprising SEQ ID NO: 877, and an LCDR3 comprising SEQ ID NO: 1093.
[0120] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 714, an HCDR2 comprising SEQ ID NO: 780, an HCDR3 comprising SEQ ID NO: 834, an LCDR1 comprising SEQ ID NO: 857, an LCDR2 comprising SEQ ID NO: 878, and an LCDR3 comprising SEQ ID NO: 1094.
[0121] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 715 or 716, an HCDR2 comprising SEQ ID NO: 781, an HCDR3 comprising SEQ ID NO: 835 or 836, an LCDR1 comprising SEQ ID NO: 858 or 859, an LCDR2 comprising SEQ ID NO: 879, and an LCDR3 comprising SEQ ID NO: 1095.
[0122] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 717, an HCDR2 comprising SEQ ID NO: 782, an HCDR3 comprising SEQ ID NO: 837, an LCDR1 comprising SEQ ID NO: 860, an LCDR2 comprising SEQ ID NO: 880, and an LCDR3 comprising SEQ ID NO: 1096.
[0123] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 718, an HCDR2 comprising SEQ ID NO: 783, an HCDR3 comprising SEQ ID NO: 838, an LCDR1 comprising SEQ ID NO: 861, an LCDR2 comprising SEQ ID NO: 881, and an LCDR3 comprising SEQ ID NO: 1097.
[0124] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 719, an HCDR2 comprising SEQ ID NO: 784, an HCDR3 comprising SEQ ID NO: 839, an LCDR1 comprising SEQ ID NO: 862, an LCDR2 comprising SEQ ID NO: 882, and an LCDR3 comprising SEQ ID NO: 1098.
[0125] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 720, an HCDR2 comprising SEQ ID NO: 785, an HCDR3 comprising SEQ ID NO: 840, an LCDR1 comprising SEQ ID NO: 863, an LCDR2 comprising SEQ ID NO: 883, and an LCDR3 comprising SEQ ID NO: 1099.
[0126] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 721, an HCDR2 comprising SEQ ID NO: 786, an HCDR3 comprising SEQ ID NO: 841, an LCDR1 comprising SEQ ID NO: 864, an LCDR2 comprising SEQ ID NO: 884, and an LCDR3 comprising SEQ ID NO: 1100.
[0127] In one aspect, provided herein is an anti-TL1A antibody having an HCDR1 comprising SEQ ID NO: 722, an HCDR2 comprising SEQ ID NO: 787, an HCDR3 comprising SEQ ID NO: 842, an LCDR1 comprising SEQ ID NO: 865, an LCDR2 comprising SEQ ID NO: 885, and an LCDR3 comprising SEQ ID NO: 1101.
[0128] In certain embodiments, the anti-TL1A antibody comprises an HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 selected from Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody A shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody B shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody C shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody D shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody E shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody F shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody G shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody H shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody B2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody C2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody D2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody E2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody F2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody G2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody H2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody I shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody I2 shown in Table 20. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody M1 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody M2 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody M3 shown in Table 15.In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M4 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M5 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M6 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M7 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M8 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M9 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M10 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M11 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M12 shown in Table 15. In certain embodiments, the anti-TL1A antibody comprises P HCDR1 (SEQ ID NO: 1 or any one of 601 to 708), P HCDR2 (SEQ ID NO: 2 to 5 or any one of 723 to 774), P HCDR3 (SEQ ID NO: 6 to 9 or any one of 788 to 828), P LCDR1 (SEQ ID NO: 10 or any one of 843 to 852), P LCDR2 (SEQ ID NO: 11 or any one of 866 to 873), and P LCDR3 (SEQ ID NO: 12 to 15 or any one of 886 to 1089), as shown in Table 15.
[0129] In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in any one of the antibodies in Table 10. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in any one of the heavy chain variable regions in Table 16. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in any one of the light chain variable regions in Table 17. CDRs may be defined by the Aho, Kabat, Chothia, or IMGT methods. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in antibody A217. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in antibody A220. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in antibody A223. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in antibody A219. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in antibody A221. In certain embodiments, the anti-TL1A antibody comprises a CDR set forth in antibody A200. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A213. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A212. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A107. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A205. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A211. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A199. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A15. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A30. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A100. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A181. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A129. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A214. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A216. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A122. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A222.In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A188. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A203. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A147. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A127. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A126. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A160. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A157. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A159. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A218. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A158. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A125. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A103. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A64. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A67. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A138. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A68. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A94. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A110. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A197. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A112. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A169. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A173. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A179. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A148. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A115. In certain embodiments, the anti-TL1A antibody comprises the CDRs described in antibody A149.In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A134. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A113. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A151. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A96. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A132. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A196. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A172. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A75. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A174. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A109. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A198. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody A170. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M1. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M2. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M3. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M4. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M5. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M6. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M7. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M8. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M9. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M10. In certain embodiments, an anti-TL1A antibody comprises the CDRs described in antibody M11. In certain embodiments, the anti-TL1A antibody comprises the CDRs set forth in antibody M12.
[0130] Exemplary Anti-TL1A Framework Regions
[0131] Tables 16-18 and Table 21 provide exemplary framework sequence regions and variable region sequences. In some embodiments, the anti-TL1A antibody comprises HC FR1 (SEQ ID NO: 304) of Table 19, HC FR2 (SEQ ID NO: 305, 313, 1317) of Table 19, HC FR3 (SEQ ID NO: 306, 307, 314, 315, 1318-1323) of Table 19, HC FR4 (SEQ ID NO: 308) of Table 19, LC FR1 (SEQ ID NO: 309) of Table 19, LC FR2 (SEQ ID NO: 310 or 1324) of Table 19, LC FR3 (SEQ ID NO: 311) of Table 19, and LC FR4 (SEQ ID NO: 312) of Table 19.
[0132] In some embodiments, the anti-TL1A antibody comprises a heavy chain framework comprising SEQ ID NO: 301 (X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2]RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYCAR[HCDR3]WGQGTTVTVSS). In some examples, X1 is Q. In some examples, X1=E. In some examples, X2=R. In some examples, X2=K. In some examples, X3=A. In some examples, X3=R. In some examples, X4=M. In some examples, X4=I. In some examples, X5=V. In some examples, X5=A. In some examples, X6=M. In some examples, X6=I. In some examples, X7=R. In some examples, X7=T. In some examples, X8=V. In some examples, X8=A. In some embodiments, X9=M. In some embodiments, X9=L. In some embodiments, X1 is at position 1 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X2 is at position 45 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X3 is at position 47 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X4 is at position 55 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X5 is at position 78 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X6 is at position 80 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X7 is at position 82 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X8 is at position 89 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X9 is at position 91 of IGHV1-46*02 as determined by Aho or Kabat numbering.
[0133] In one aspect, provided herein is a first embodiment of an anti-TL1A antibody comprising a heavy chain framework comprising IGHV1-46*02, or a variant thereof, wherein the variant comprises about 1 to about 9 amino acid substitutions, or about 1 to about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from the IGHV1-46*02 framework. Additional embodiments include: (2) the anti-TL1A of embodiment (1), wherein the heavy chain framework comprises SEQ ID NO: 301; (3) the anti-TL1A of embodiment 2, wherein X1 = Q; (4) the anti-TL1A of embodiment 2, wherein X1 = E; (5) the anti-TL1A of any one of embodiments 2 to 4, wherein X2 = R; or (6) the anti-TL1A of any one of embodiments 2 to 4, wherein X2 = K. (7) Anti-TL1A according to any one of embodiments 2 to 6, wherein X3=A. (8) Anti-TL1A according to any one of embodiments 2 to 6, wherein X3=R. (9) Anti-TL1A according to any one of embodiments 2 to 8, wherein X4=M. (10) Anti-TL1A according to any one of embodiments 2 to 8, wherein X4=I. (11) Anti-TL1A according to any one of embodiments 2 to 10, wherein X5=V. (12) Anti-TL1A according to any one of embodiments 2 to 10, wherein X5=A. (13) Anti-TL1A according to any one of embodiments 2 to 12, wherein X6=M. (14) Anti-TL1A according to any one of embodiments 2 to 12, wherein X6=I. (15) Anti-TL1A according to any one of embodiments 2 to 14, wherein X7=R. (16) Anti-TL1A according to any one of embodiments 2 to 14, wherein X7=T. (17) Anti-TL1A according to any one of embodiments 2 to 16, wherein X8=V. (18) The anti-TL1A according to any one of embodiments 2 to 16, wherein X8 = A. (19) The anti-TL1A according to any one of embodiments 2 to 18, wherein X9 = M. (20) The anti-TL1A according to any one of embodiments 2 to 4, wherein X9 = L. (21) The anti-TL1A according to any one of embodiments 1 to 20, comprising antibody A. (22) The anti-TL1A according to any one of embodiments 1 to 20, comprising antibody B. (23) The anti-TL1A according to any one of embodiments 1 to 20, comprising antibody C.Anti-TL1A according to any one of embodiments 1 to 20. (24) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody D. (25) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody E. (26) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody F. (27) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody G or I. (28) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody H. (29) The anti-TL1A antibody of any one of embodiments 1 to 28, comprising a human IgG1 Fc region, comprising: (a) 297A, 297Q, 297G, or 297D; (b) 279F, 279K, or 279L; (c) 228P; (d) 235A, 235E, 235G, 235Q, 235R, or 235S; (e) 237A, 237E, 237K, 237N, or 237R; (f) 234A, 234V, or 234F; (g) 233P; (h) 328A; (i) 327Q or 327T; (j) 329A, 329G, 329Y, or 329R; (k) 331S; (l) 236F, according to Kabat numbering. or 236R, (m) 238A, 238E, 238G, 238H, 238I, 238V, 238W, or 238Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 254I, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265A, (t) 26 7G, 267H, 267I, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G, or 292I, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 311S, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 343I or 343V, (jj) 373A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (ll) 380D,(mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 434I, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235 E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgG1σ), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (lll) A330L, (mmm) P331A or P331S, or (nnn) any combination of (a)-(uu). As used herein, any combination of groups, e.g., (a) through (uu), includes at least about two or more items of the group, e.g., any combination of groups (a) through (uu) includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and up to 47, or all, of the group members. (30) (i) a human IgG4 Fc region, or (ii) a human IgG4 Fc region comprising, according to Kabat numbering, (a) S228P, (b) S228P and L235E, or (c) S228P, F234A, and L235A;(31) The anti-TL1A of any one of embodiments 1 to 28, comprising a human IgG2 Fc region; an IgG2-IgG4 cross-subclass Fc region; an IgG2-IgG3 cross-subclass Fc region; an IgG2 comprising H268Q, V309L, A330S, and P331S (IgG2m4); or an IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, and P331S (IgG2σ). (32) The anti-TL1A of any one of embodiments 1 to 31, comprising a heavy chain Fc region comprising any one of SEQ ID NOs: 320 to 362. (33) The anti-TL1A of any one of embodiments 1 to 32, comprising a light chain constant region comprising SEQ ID NO: 319. (34) The anti-TL1A antibody of any one of embodiments 1 to 33, comprising a light chain comprising a light chain framework comprising IGKV3-20*01 or a variant thereof, wherein the variant comprises about 1 to about 2 substitutions, or about 1 to about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. (35) The anti-TL1A antibody of embodiment 34, wherein X10 is L. (36) The anti-TL1A antibody of embodiment 34, wherein X10 is P. (37) The anti-TL1A antibody of any one of embodiments 34 to 36, wherein X11 is L. (38) The anti-TL1A antibody of any one of embodiments 34 to 36, wherein X11 is W.
[0134] In some embodiments, the anti-TL1A antibody comprises a heavy chain framework comprising SEQ ID NO: 302 (X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2]RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYC[HCDR3]WGQGTTVTVSS). In some examples, X1 is Q. In some examples, X1=E. In some examples, X2=R. In some examples, X2=K. In some examples, X3=A. In some examples, X3=R. In some examples, X4=M. In some examples, X4=I. In some examples, X5=V. In some examples, X5=A. In some examples, X6=M. In some examples, X6=I. In some examples, X7=R. In some examples, X7=T. In some examples, X8=V. In some examples, X8=A. In some embodiments, X9=M. In some embodiments, X9=L. In some embodiments, X1 is at position 1 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X2 is at position 45 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X3 is at position 47 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X4 is at position 55 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X5 is at position 78 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X6 is at position 80 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X7 is at position 82 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X8 is at position 89 of IGHV1-46*02 as determined by Aho or Kabat numbering. In some embodiments, X9 is at position 91 of IGHV1-46*02 as determined by Aho or Kabat numbering.
[0135] In one aspect, provided herein is another first embodiment of an anti-TL1A antibody comprising a heavy chain framework comprising IGHV1-46*02, or a variant thereof, wherein the variant comprises about 1 to about 9 amino acid substitutions, or about 1 to about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from the IGHV1-46*02 framework. Additional embodiments include: (2) the anti-TL1A of embodiment (1), wherein the heavy chain framework comprises SEQ ID NO: 302; (3) the anti-TL1A of embodiment 2, wherein X1 = Q; (4) the anti-TL1A of embodiment 2, wherein X1 = E; (5) the anti-TL1A of any one of embodiments 2 to 4, wherein X2 = R; or (6) the anti-TL1A of any one of embodiments 2 to 4, wherein X2 = K. (7) Anti-TL1A according to any one of embodiments 2 to 6, wherein X3=A. (8) Anti-TL1A according to any one of embodiments 2 to 6, wherein X3=R. (9) Anti-TL1A according to any one of embodiments 2 to 8, wherein X4=M. (10) Anti-TL1A according to any one of embodiments 2 to 8, wherein X4=I. (11) Anti-TL1A according to any one of embodiments 2 to 10, wherein X5=V. (12) Anti-TL1A according to any one of embodiments 2 to 10, wherein X5=A. (13) Anti-TL1A according to any one of embodiments 2 to 12, wherein X6=M. (14) Anti-TL1A according to any one of embodiments 2 to 12, wherein X6=I. (15) Anti-TL1A according to any one of embodiments 2 to 14, wherein X7=R. (16) Anti-TL1A according to any one of embodiments 2 to 14, wherein X7=T. (17) Anti-TL1A according to any one of embodiments 2 to 16, wherein X8=V. (18) The anti-TL1A according to any one of embodiments 2 to 16, wherein X8 = A. (19) The anti-TL1A according to any one of embodiments 2 to 18, wherein X9 = M. (20) The anti-TL1A according to any one of embodiments 2 to 4, wherein X9 = L. (21) The anti-TL1A according to any one of embodiments 1 to 20, comprising antibody A. (22) The anti-TL1A according to any one of embodiments 1 to 20, comprising antibody B. (23) The anti-TL1A according to any one of embodiments 1 to 20, comprising antibody C.Anti-TL1A according to any one of embodiments 1 to 20. (24) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody D. (25) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody E. (26) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody F. (27) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody G or I. (28) Anti-TL1A according to any one of embodiments 1 to 20, comprising antibody H. (29) The anti-TL1A antibody of any one of embodiments 1 to 28, comprising a human IgG1 Fc region, comprising: (a) 297A, 297Q, 297G, or 297D; (b) 279F, 279K, or 279L; (c) 228P; (d) 235A, 235E, 235G, 235Q, 235R, or 235S; (e) 237A, 237E, 237K, 237N, or 237R; (f) 234A, 234V, or 234F; (g) 233P; (h) 328A; (i) 327Q or 327T; (j) 329A, 329G, 329Y, or 329R; (k) 331S; (l) 236F, according to Kabat numbering. or 236R, (m) 238A, 238E, 238G, 238H, 238I, 238V, 238W, or 238Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 254I, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265A, (t) 26 7G, 267H, 267I, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G, or 292I, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 311S, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 343I or 343V, (jj) 373A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (ll) 380D,(mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 434I, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235 E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgG1σ), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (lll) A330L, (mmm) P331A or P331S, or (nnn) any combination of (a)-(uu). (30) The anti-TL1A of any one of embodiments 1 to 28, comprising: (i) a human IgG4 Fc region; or (ii) a human IgG4 Fc region comprising, according to Kabat numbering, (a) S228P and L235E, or (b) S228P, F234A, and L235A. (31) The anti-TL1A of any one of embodiments 1 to 28, comprising: a human IgG2 Fc region; an IgG2-IgG4 cross-subclass Fc region; an IgG2-IgG3 cross-subclass Fc region; an IgG2 comprising H268Q, V309L, A330S, and P331S (IgG2m4); or an IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, and P331S (IgG2σ). (32) The anti-TL1A antibody according to any one of embodiments 1 to 31, comprising a heavy chain Fc region comprising any one of SEQ ID NOs: 320 to 362. (33) The anti-TL1A antibody according to any one of embodiments 1 to 31, comprising a light chain constant region comprising SEQ ID NO: 319.(34) The anti-TL1A antibody of any one of embodiments 1 to 33, comprising a light chain comprising a light chain framework comprising IGKV3-20*01 or a variant thereof, wherein the variant comprises about 1 to about 2 substitutions, or about 1 to about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. (35) The anti-TL1A antibody of embodiment 34, wherein X10 is L. (36) The anti-TL1A antibody of embodiment 34, wherein X10 is P. (37) The anti-TL1A antibody of any one of embodiments 34 to 36, wherein X11 is L. (38) The anti-TL1A antibody of any one of embodiments 34 to 36, wherein X11 is W.
[0136] In some embodiments, the anti-TL1A antibody comprises a light chain framework comprising SEQ ID NO: 303 (EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK). In some examples, X10 is L. In some examples, X10 is P. In some examples, X11 is L. In some examples, X11 is W. In some embodiments, X10 is at position 54 of IGKV3-20*01 as determined by Aho or Kabat numbering. In some embodiments, X11 is at position 55 of IGKV3-20*01 as determined by Aho or Kabat numbering.
[0137] In some embodiments, the anti-TL1A antibody comprises a heavy chain framework comprising IGHV1-46*02. In some embodiments, the anti-TL1A antibody comprises a heavy chain framework comprising a variant of IGHV1-46*02 comprising about 1 to about 20 amino acid substitutions from SEQ ID NO: 316. In some embodiments, the anti-TL1A antibody comprises a heavy chain framework comprising a variant of IGHV1-46*02 comprising about 1 to about 9 amino acid substitutions from SEQ ID NO: 316. In some embodiments, the anti-TL1A antibody comprises a heavy chain framework comprising a variant of IGHV1-46*02 comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework from SEQ ID NO: 316. In some examples, the heavy chain framework substitution comprises Q1E, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises R45K, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises A47R, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises M55I, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises V78A, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises M80I, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises R82T, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises V89A, as determined by Aho or Kabat numbering. In some examples, the heavy chain framework substitution comprises M91L, as determined by Aho or Kabat numbering.
[0138] In some embodiments, the anti-TL1A antibody comprises a light chain framework comprising IGKV3-20*01. In some embodiments, the anti-TL1A antibody comprises a variant of IGKV3-20*01 comprising about one to about 20 amino acid substitutions from SEQ ID NO: 317. In some embodiments, the anti-TL1A antibody comprises a variant of IGKV3-20*01 comprising about one amino acid substitution from SEQ ID NO: 317. In some embodiments, the anti-TL1A antibody comprises a light chain framework comprising a variant of IGKV3-20*01 comprising about two amino acid substitutions from SEQ ID NO: 317. In some embodiments, the anti-TL1A antibody comprises a light chain framework comprising a variant of IGKV3-20*01 comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework from SEQ ID NO: 317. In some examples, the light chain framework substitution comprises Q1E, as determined by Aho or Kabat numbering. In some examples, the light chain framework substitution comprises R45K, as determined by Aho or Kabat numbering.
[0139] In some embodiments, the anti-TL1A antibody comprises a heavy chain FR1 set forth in SEQ ID NO: 304. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR2 set forth in SEQ ID NO: 305. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR2 set forth in SEQ ID NO: 313. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR2 set forth in SEQ ID NO: 1317. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 306. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 307. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 314. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 315. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 1318. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 1319. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 1320. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 1321. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 1322. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR3 set forth in SEQ ID NO: 1323. In some embodiments, the anti-TL1A antibody comprises a heavy chain FR4 set forth in SEQ ID NO: 308. In some embodiments, the anti-TL1A antibody comprises a light chain FR1 set forth in SEQ ID NO: 309. In some embodiments, the anti-TL1A antibody comprises a light chain FR2 set forth in SEQ ID NO: 310. In some embodiments, the anti-TL1A antibody comprises a light chain FR2 set forth in SEQ ID NO: 1324. In some embodiments, the anti-TL1A antibody comprises a light chain FR3 set forth in SEQ ID NO: 311. In some embodiments, the anti-TL1A antibody comprises a light chain FR3 set forth in SEQ ID NO: 1325. In some embodiments, the anti-TL1A antibody comprises a light chain FR4 set forth in SEQ ID NO:312.
[0140] In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in any one of the antibodies in Table 1, the framework region being defined by the Aho or Kabat, Chothia, or IMGT methods. In certain embodiments, an anti-TL1A antibody comprises a C framework region set forth in antibody A217. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A220. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A223. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A219. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A221. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A200. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A213. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A212. In certain embodiments, an anti-TL1A antibody comprises a framework region set forth in antibody A107. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A205. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A211. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A199. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A15. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A30. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A100. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A181. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A129. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A214. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A216. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A122.In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A222. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A188. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A203. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A147. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A127. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A126. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A160. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A157. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A159. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A218. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A158. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A125. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A103. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A64. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A67. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A138. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A68. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A94. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A110. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A197. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A112. In certain embodiments, the anti-TL1A antibody comprises a framework region described in antibody A169.In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A173. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A179. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A148. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A115. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A149. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A134. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A113. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A151. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A96. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A132. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A196. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A172. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A75. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A174. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A109. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A198. In certain embodiments, an anti-TL1A antibody comprises a framework region described in antibody A170.
[0141] In certain embodiments, the anti-TL1A antibody comprises a heavy chain framework region set forth in any one of the antibodies in Table 16 and a light chain framework region set forth in any one of the antibodies in Table 17, wherein the framework regions are defined by the Aho or Kabat, Chothia, or IMGT methods. Exemplary Anti-TL1A Variable Regions
[0142] In one aspect, provided herein is an anti-TL1A antibody comprising a heavy chain variable region comprising an amino acid sequence at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 101-135, and a light chain variable region at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to at least one of SEQ ID NOs: 201-206.
[0143] Further provided herein is a first embodiment of an anti-TL1A antibody comprising a heavy chain variable region and a light chain variable region. Non-limiting additional embodiments include: (Embodiment 2) the anti-TL1A antibody of Embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 101. (Embodiment 3) the anti-TL1A antibody of Embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101. (Embodiment 4) the anti-TL1A antibody of Embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 101. (Embodiment 5) the anti-TL1A antibody of Embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 102. (Embodiment 6) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102. (Embodiment 7) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 102. (Embodiment 8) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 103. (Embodiment 9) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103. (Embodiment 10) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array having approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 103.
[0144] (Embodiment 11) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 104. (Embodiment 12) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104. (Embodiment 13) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 104. (Embodiment 14) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 105. (Embodiment 15) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105. (Embodiment 16) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 105. (Embodiment 17) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 106. (Embodiment 18) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106. (Embodiment 19) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 106. (Embodiment 20) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 107. (Embodiment 21) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107. (Embodiment 22) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that has about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 107.
[0145] (Embodiment 23) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 108. (Embodiment 24) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108. (Embodiment 25) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 108. (Embodiment 26) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 109. (Embodiment 27) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109. (Embodiment 28) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 109. (Embodiment 29) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 110. (Embodiment 30) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110. (Embodiment 31) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 110. (Embodiment 32) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 111. (Embodiment 33) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111. (Embodiment 34) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 111. (Embodiment 35) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 112.(Embodiment 36) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112. (Embodiment 37) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 112. (Embodiment 38) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 113. (Embodiment 39) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 113. (Embodiment 40) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array having approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 113.
[0146] (Embodiment 41) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 114. (Embodiment 42) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114. (Embodiment 43) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 114. (Embodiment 44) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 115. (Embodiment 45) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 115. (Embodiment 46) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 115. (Embodiment 47) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 116. (Embodiment 48) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116. (Embodiment 49) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 116. (Embodiment 50) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 117. (Embodiment 51) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117. (Embodiment 52) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that has about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 117.
[0147] (Embodiment 53) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 118. (Embodiment 54) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 118. (Embodiment 55) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 118. (Embodiment 56) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 119. (Embodiment 57) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119. (Embodiment 58) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 119. (Embodiment 59) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 120. (Embodiment 60) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 120. (Embodiment 61) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 120.
[0148] (Embodiment 62) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 121. (Embodiment 63) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121. (Embodiment 64) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 121. (Embodiment 65) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 122. (Embodiment 66) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122. (Embodiment 67) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 122. (Embodiment 68) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 123. (Embodiment 69) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 123. (Embodiment 70) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 123. (Embodiment 71) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 124. (Embodiment 72) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 124. (Embodiment 73) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that has about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 124.
[0149] (Embodiment 74) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 125. (Embodiment 75) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 125. (Embodiment 76) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 125. (Embodiment 77) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 126. (Embodiment 78) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 126. (Embodiment 79) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 126. (Embodiment 80) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 127. (Embodiment 81) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127. (Embodiment 82) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 127. (Embodiment 83) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 128. (Embodiment 84) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128. (Embodiment 85) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that has about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 128.
[0150] (Embodiment 86) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 129. (Embodiment 87) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 129. (Embodiment 88) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 129. (Embodiment 89) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 130. (Embodiment 90) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 130. (Embodiment 91) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 130. (Embodiment 92) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 131. (Embodiment 93) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 131. (Embodiment 94) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 131. (Embodiment 95) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 132. (Embodiment 96) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 132. (Embodiment 97) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that has about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 132.
[0151] (Embodiment 98) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 133. (Embodiment 99) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 133. (Embodiment 100) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 133. (Embodiment 101) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 134. (Embodiment 102) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134. (Embodiment 103) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 134. (Embodiment 104) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 135. (Embodiment 105) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135. (Embodiment 106) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 135.
[0152] (Embodiment 107) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises SEQ ID NO: 201. (Embodiment 108) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 109) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 201. (Embodiment 110) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises SEQ ID NO: 202. (Embodiment 111) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 112) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 202. (Embodiment 113) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises SEQ ID NO: 203. (Embodiment 114) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203. (Embodiment 115) The anti-TL1A antibody of any one of embodiments 1 to 106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 203. (Embodiment 116) The anti-TL1A antibody of any one of embodiments 1 to 106, wherein the light chain variable region comprises SEQ ID NO: 204. (Embodiment 117) The anti-TL1A antibody of any one of embodiments 1 to 106, wherein the light chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.(Embodiment 118) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 204. (Embodiment 119) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises SEQ ID NO: 205. (Embodiment 120) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 121) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 205. (Embodiment 122) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises SEQ ID NO: 206. (Embodiment 123) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 206. (Embodiment 124) The anti-TL1A antibody of any one of Embodiments 1 to 106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions compared to SEQ ID NO: 206.
[0153] (Embodiment 125) The anti-TL1A antibody of embodiment 1, comprising A217. (Embodiment 126) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 127) The anti-TL1A antibody of embodiment 1, comprising A220. (Embodiment 128) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 129) The anti-TL1A antibody of embodiment 1, comprising A223. (Embodiment 130) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 131) The anti-TL1A antibody of embodiment 1, comprising A219. (Embodiment 132) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 133) The anti-TL1A antibody of embodiment 1, comprising A221. (Embodiment 134) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.
[0154] (Embodiment 135) The anti-TL1A antibody of embodiment 1, comprising A200. (Embodiment 136) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 137) The anti-TL1A antibody of embodiment 1, comprising A213. (Embodiment 138) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 139) The anti-TL1A antibody of embodiment 1, comprising A212. (Embodiment 140) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 141) The anti-TL1A antibody of embodiment 1, comprising A107. (Embodiment 142) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 143) The anti-TL1A antibody of embodiment 1, comprising A205. (Embodiment 144) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202.
[0155] (Embodiment 145) The anti-TL1A antibody of embodiment 1, comprising A211. (Embodiment 146) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 147) The anti-TL1A antibody of embodiment 1, comprising A199. (Embodiment 148) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 109, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 201. (Embodiment 149) The anti-TL1A antibody of embodiment 1, comprising A15. (Embodiment 150) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 203. (Embodiment 151) The anti-TL1A antibody of embodiment 1, comprising A30. (Embodiment 152) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 153) The anti-TL1A antibody of embodiment 1, comprising A100. (Embodiment 154) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.
[0156] (Embodiment 155) The anti-TL1A antibody of embodiment 1, comprising A181. (Embodiment 156) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 157) The anti-TL1A antibody of embodiment 1, comprising A129. (Embodiment 158) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 159) The anti-TL1A antibody of embodiment 1, comprising A214. (Embodiment 160) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 161) The anti-TL1A antibody of embodiment 1, comprising A216. (Embodiment 162) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 163) The anti-TL1A antibody of embodiment 1, comprising A122. (Embodiment 164) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 113, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.
[0157] (Embodiment 165) The anti-TL1A antibody of embodiment 1, comprising A222. (Embodiment 166) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 167) The anti-TL1A antibody of embodiment 1, comprising A188. (Embodiment 168) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 115, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 169) The anti-TL1A antibody of embodiment 1, comprising A203. (Embodiment 170) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 171) The anti-TL1A antibody of embodiment 1, comprising A147. (Embodiment 172) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 173) The anti-TL1A antibody of embodiment 1, comprising A127. (Embodiment 174) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 118, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.
[0158] (Embodiment 175) The anti-TL1A antibody of embodiment 1, comprising A126. (Embodiment 176) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 177) The anti-TL1A antibody of embodiment 1, comprising A160. (Embodiment 178) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 179) The anti-TL1A antibody of embodiment 1, comprising A157. (Embodiment 180) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 181) The anti-TL1A antibody of embodiment 1, comprising A159. (Embodiment 182) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 183) The anti-TL1A antibody of embodiment 1, comprising A218. (Embodiment 184) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.
[0159] (Embodiment 185) The anti-TL1A antibody of embodiment 1, comprising A158. (Embodiment 186) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 187) The anti-TL1A antibody of embodiment 1, comprising A125. (Embodiment 188) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 189) The anti-TL1A antibody of embodiment 1, comprising A103. (Embodiment 190) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 120, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 191) The anti-TL1A antibody of embodiment 1, comprising A64. (Embodiment 192) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 193) The anti-TL1A antibody of embodiment 1, comprising A67. (Embodiment 194) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202.
[0160] (Embodiment 195) The anti-TL1A antibody of embodiment 1, comprising A138. (Embodiment 196) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 197) The anti-TL1A antibody of embodiment 1, comprising A68. (Embodiment 198) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 123, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 202. (Embodiment 199) The anti-TL1A antibody of embodiment 1, comprising A94. (Embodiment 200) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 124, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 202. (Embodiment 201) The anti-TL1A antibody of embodiment 1, comprising A110. (Embodiment 202) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 125, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 203) The anti-TL1A antibody of embodiment 1, comprising A197. (Embodiment 204) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205.
[0161] (Embodiment 205) The anti-TL1A antibody of embodiment 1, comprising A112. (Embodiment 206) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 207) The anti-TL1A antibody of embodiment 1, comprising A169. (Embodiment 208) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 126, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 209) The anti-TL1A antibody of embodiment 1, comprising A173. (Embodiment 210) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 211) The anti-TL1A antibody of embodiment 1, comprising A179. (Embodiment 212) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 213) The anti-TL1A antibody of embodiment 1, comprising A148. (Embodiment 214) An anti-TL1A antibody described in embodiment 1, wherein the heavy chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121, and the light chain variable region comprises an array that is at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.
[0162] (Embodiment 215) The anti-TL1A antibody of embodiment 1, comprising A115. (Embodiment 216) The anti-TL1A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 217) The anti-TL1A antibody of embodiment 1, comprising A149. (Embodiment 218) The anti-TL1A antibody of embodiment 1, wherein the heavy chain va...
Claims
1. 1. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: At least three polymorphisms are detected in a sample obtained from the subject that predict a positive therapeutic response of the subject to treatment with the TL1A inhibitor with a positive predictive value or specificity of at least about 51%; and The TL1A inhibitor is an antibody or antigen-binding fragment thereof that competes with a reference antibody for binding to human TL1A, the antibody or antigen-binding fragment comprising a heavy chain variable region comprising: (a) an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:1; (b) an HCDR2 comprising the amino acid sequence set forth in any one of SEQ ID NOs:2-5; and (c) an HCDR3 comprising the amino acid sequence set forth in any one of SEQ ID NOs:6-9; and a light chain variable region comprising: (d) an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:10; (e) an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:11; and (f) an LCDR3 comprising the amino acid sequence set forth in any one of SEQ ID NOs:12-15.
2. The at least three polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2 2. The TL1A inhibitor of claim 1, comprising a proxy polymorphism in linkage disequilibrium therewith as determined by
3. 1. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: At least three polymorphisms are present: rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12934476, rs12934477, rs12934478 ... s12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2 or a proxy polymorphism in linkage disequilibrium therewith as determined by The TL1A inhibitor is an antibody or antigen-binding fragment thereof that competes with a reference antibody for binding to human TL1A, the antibody or antigen-binding fragment comprising a heavy chain variable region comprising: (a) an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:1; (b) an HCDR2 comprising the amino acid sequence set forth in any one of SEQ ID NOs:2-5; and (c) an HCDR3 comprising the amino acid sequence set forth in any one of SEQ ID NOs:6-9; and a light chain variable region comprising: (d) an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:10; (e) an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:11; and (f) an LCDR3 comprising the amino acid sequence set forth in any one of SEQ ID NOs:12-15.
4. 1. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: At least three polymorphisms are present: rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12934476, rs12934477, rs12934478 ... s12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2 or a proxy polymorphism in linkage disequilibrium therewith as determined by The TL1A inhibitor is an antibody or antigen-binding fragment thereof that binds to TL1A, comprising a heavy chain variable region comprising (a) an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, (b) an HCDR2 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 2 to 5, and (c) an HCDR3 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 6 to 9, and a light chain variable region comprising (d) an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 10, (e) an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 11, and (f) an LCDR3 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 12 to 15. (i) the antibody or antigen-binding fragment has the following sequence according to the Kabat numbering: (a) 297A, 297Q, 297G, or 297D; (b) 279F, 279K, or 279L; (c) 228P; (d) 235A, 235E, 235G, 235Q, 235R, or 235S; (e) 237A, 237E, 237K, 237N, or 237R; (f) 234A, 234V, or 234F; (g) 233P; (h) 328A; (i) 327Q or 327T; (j) 329A, 329G, 329Y, or 329R; (k) 33 1S, (l) 236F or 236R, (m) 238A, 238E, 238G, 238H, 238I, 238V, 238W, or 238Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 254I, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265A, (t) 267G, 267H, 267I, or 267K, (u) 268K, (v) 269 N, or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G, or 292I, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 311S, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 343I or 343V, (jj) 373A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (ll) 380D , (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 434I, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S,(zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S, (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgG1σ), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (ee) G (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (lll) A330L, (mmm) P331A or P331S, or (nnn) any combination of two or more selected from (a)-(uu); (ii) the antibody or antigen-binding fragment comprises an Fc region comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 320-362; (iii) the antigen-binding fragment of the antibody comprises a fragment crystallizable (Fc) region that has reduced antibody-dependent cell-mediated cytotoxicity (ADCC) function compared to human IgG1 and / or reduced complement-dependent cytotoxicity (CDC) function compared to human IgG1; wherein, optionally, said ADCC function is reduced by at least about 50% compared to human IgG1, and / or said CDC function is reduced by at least about 50% compared to human IgG1; (iv) the antibody or antigen-binding fragment comprises a human IgG1 Fc region comprising SEQ ID NO: 320; (v) the antibody or antigen-binding fragment has the following sequence according to the Kabat numbering: 329A, 329G, 329Y, 331S, 236F, 236R, 238A, 238E, 238G, 238H, 238I, 238V, 238W, 238Y, 248A, 254D, 254E, 254G, 254H, 254I, 254N, Substitutions selected from 254P, 254Q, 254T, 254V, 264S, 265H, 265K, 265S, 265Y, 265A, 267G, 267H, 267I, 267K, 434I, 438G, 439E, 439H, 439Q, 440A, 440D, 440E, 440F, 440M, 440T and 440V or (vi) the antibody or antigen-binding fragment comprises an Fc comprising any one of SEQ ID NOs:401-413, or a sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:401-413; A TL1A inhibitor according to any one of claims 1, 3 or 4. (i) the positive predictive value is greater than or equal to about 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%; and / or (ii) the specificity is greater than or equal to about 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%; A TL1A inhibitor according to any one of claims 1, 3 or 4.
7. The at least three polymorphisms are (i) rs6478109, rs56124762, and rs1892231; (ii) rs6478109, rs56124762, and rs16901748; (iii) rs6478109, rs1892231, and rs16901748; (iv) rs56124762, rs1892231, and rs16901748, (v) rs6478109, rs2070558, and rs1892231; (vi) rs6478109, rs2070558, and rs16901748, (vii) rs6478109, rs1892231, and rs16901748; (viii) rs2070558, rs1892231, and rs16901748; (ix) rs6478109, rs2070561, and rs1892231; (x) rs6478109, rs2070561, and rs16901748; (xi) rs6478109, rs1892231, and rs16901748, (xii) rs2070561, rs1892231, and rs16901748, (xiii) rs6478109, rs7935393, and rs1892231; (xiv) rs6478109, rs7935393, and rs9806914, (xv) rs6478109, rs7935393, and rs7278257, (xvi) rs6478109, rs7935393, and rs2070557, (xvii) rs6478109, rs1892231, and rs9806914, (xviii) rs6478109, rs1892231, and rs7278257; (xix) rs6478109, rs1892231, and rs2070557, (xx) rs6478109, rs9806914, and rs7278257; (xxi) rs6478109, rs9806914, and rs2070557, (xxii) rs6478109, rs7278257, and rs2070557, (xxiii) rs7935393, rs1892231, and rs9806914, (xxiv) rs7935393, rs1892231, and rs7278257, (xxv) rs7935393, rs1892231, and rs2070557, (xxvi) rs7935393, rs9806914, and rs7278257, (xxvii) rs7935393, rs9806914, and rs2070557, (xxviii) rs7935393, rs7278257, and rs2070557; (xxvix) rs1892231, rs9806914, and rs7278257; (xxx) rs1892231, rs9806914, and rs2070557, (xxxi) rs1892231, rs7278257, and rs2070557, (xxxii) rs9806914, rs7278257, and rs2070557, (xxxiii) rs6478109, rs56124762, and rs1892231; (xxxiv) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs9806914, and rs2297437; (xxxv) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs9806914, rs1326860, and rs2815844; (xxxvi) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs2297437, rs1326860, and rs12457255; (xxxvii) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs1326860, rs12457255, and rs2815844; (xxxviii) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs12457255, rs2815844, and rs10974900; (xxxix) rs6478109, rs56124762, rs1892231, rs16901748, rs7935393, rs1326860, rs12457255, and rs2815844; (xl) rs6478109, rs56124762, rs1892231, rs16901748, rs9806914, rs1326860, rs12457255, and rs10974900; (xli) rs6478109, rs56124762, rs1892231, rs16901748, rs2297437, rs1326860, rs12457255, and rs2409750; (xlii) rs6478109, rs56124762, rs1892231, rs16901748, rs2297437, rs12457255, rs2815844, and s2409750; (xliii) rs6478109, rs56124762, rs1892231, rs16901748, rs1326860, rs12457255, rs2815844, and rs10974900; (xliv) rs6478109, rs56124762, rs1892231, rs16901748, rs12457255, rs2815844, rs10974900, and rs1541020; (xlv) rs6478109, rs56124762, rs1892231, rs16901748, rs2815844, rs10974900, rs2409750, and rs7759385; (xlvi) rs6478109, rs56124762, rs1892231, rs16901748, rs10974900, rs1541020, rs4942248, and rs7759385; (xlvii) rs6478109, rs56124762, rs1892231, rs16901748, rs2409750, rs1541020, rs4942248, and rs7759385; (xlviii) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs7935393, rs2297437, and rs1326860; (xlix) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs9806914, rs2297437, and rs12457255; (l) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs2297437, rs12457255, and rs2409750; or (li) rs6478109, rs56124762, rs1892231, rs16901748, rs12934476, rs2297437, rs4942248, and rs7759385; A TL1A inhibitor according to any one of claims 1, 3 or 4.
8. The at least three polymorphisms are rs16901748, rs1892231, rs56124762, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2 The TL1A inhibitor of any one of claims 1, 3 or 4, further comprising additional polymorphisms, including proxy polymorphisms in linkage disequilibrium therewith as determined by a qPCR test, or a combination thereof.
9. The inflammatory, fibrotic or fibrostenosing disease or condition comprises inflammatory bowel disease, Crohn's disease, obstructive Crohn's disease, ulcerative colitis, intestinal fibrosis, intestinal fibrostenosing, rheumatoid arthritis, pulmonary fibrosis, scleroderma, or primary sclerosing cholangitis; wherein optionally said Crohn's disease is ileal, ileocolonic, or colonic Crohn's disease; wherein optionally the subject is non-responsive or has lost or is at risk of developing non-responsiveness to standard therapy, including glucocorticosteroids, anti-TNF therapy, anti-a4-b7 therapy, anti-IL 12p40 therapy, or a combination thereof; A TL1A inhibitor according to any one of claims 1, 3 or 4.
10. The TL1A inhibitor of any one of claims 1, 3 or 4, further comprising determining whether the subject having an inflammatory, fibrotic or fibrostenosing disease or condition is suitable for treatment with an inhibitor of TL1A activity or expression based at least in part on the at least three polymorphisms detected in the sample.
11. The TL1A inhibitor of claim 1 , 3 or 4, further comprising obtaining the sample from the subject or having obtained the sample from the subject.
12. 5. The TL1A inhibitor of claim 1, 3 or 4, wherein the at least three polymorphisms are detected using an assay comprising a quantitative polymerase chain reaction (qPCR), a nucleic acid sequencing reaction, or a genotyping array.
13. The at least three polymorphisms are (i) three polymorphisms selected from Table 1; (ii) four polymorphisms selected from Table 1; (iii) five polymorphisms selected from Table 1; (iv) six polymorphisms selected from Table 1; (v) seven polymorphisms selected from Table 1; (vi) eight polymorphisms from one or more of the 8-SNP models provided in Table 25; (vii) nine polymorphisms selected from Table 1; or (viii) ten polymorphisms selected from Table 1. The TL1A inhibitor of any one of claims 1, 3 or 4.
14. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: at least four polymorphisms are detected in a sample obtained from the subject that predict a positive therapeutic response of the subject to treatment with the TL1A inhibitor with a positive predictive value or specificity of at least about 51%; The at least four polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2, proxy polymorphisms in linkage disequilibrium therewith as determined by 2, or a combination thereof; and wherein the TL1A inhibitor is an antibody or an antigen-binding fragment thereof; TL1A inhibitors.
15. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: at least five polymorphisms are detected in a sample obtained from the subject that predict a positive therapeutic response of the subject to treatment with the TL1A inhibitor with a positive predictive value or specificity of at least about 51%; The at least five polymorphisms are rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2, proxy polymorphisms in linkage disequilibrium therewith as determined by 2, or a combination thereof; and wherein the TL1A inhibitor is an antibody or an antigen-binding fragment thereof; TL1A inhibitors.
16. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: at least six polymorphisms are detected in a sample obtained from the subject that predict a positive therapeutic response of the subject to treatment with the TL1A inhibitor with a positive predictive value or specificity of at least about 51%; The at least six polymorphisms are: rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2, proxy polymorphisms in linkage disequilibrium therewith as determined by 2, or a combination thereof; and wherein the TL1A inhibitor is an antibody or an antigen-binding fragment thereof; TL1A inhibitors.
17. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: at least seven polymorphisms are detected in a sample obtained from the subject that predict a positive therapeutic response of the subject to treatment with the TL1A inhibitor with a positive predictive value or specificity of at least about 51%; The at least seven polymorphisms are: rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2, proxy polymorphisms in linkage disequilibrium therewith as determined by 2, or a combination thereof; and wherein the TL1A inhibitor is an antibody or an antigen-binding fragment thereof; TL1A inhibitors.
18. An inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression (TL1A inhibitor) for use in treating an inflammatory, fibrotic, or fibrostenosing disease or condition in a subject, comprising: at least eight polymorphisms are detected in a sample obtained from the subject that predict a positive therapeutic response of the subject to treatment with the TL1A inhibitor with a positive predictive value or specificity of at least about 51%; The at least eight polymorphisms are: rs16901748, rs56124762, rs6478109, rs1892231, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs12934476, rs12457255, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs7935393, rs1690492, rs420726, rs7759385, rs10974900, rs1326860, rs2548147, rs2815844, rs889702, rs9806914, rs7278257, or rs11221332, or an R of at least 0.85 2, proxy polymorphisms in linkage disequilibrium therewith as determined by 2, or a combination thereof; and wherein the TL1A inhibitor is an antibody or an antigen-binding fragment thereof; TL1A inhibitors.
